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The brain accounts for 20% of overall energy metabolism in the body though it 
just comprises 2% of the total body mass but has a limited capacity of storing energy 
unlike other critical organs in the body such as the heart and liver. This energy along with 
oxygen and nutrients is supplied by cerebral blood flow (CBF), any interruption of which 
can cease the brain function within seconds with a potential irreversible neuronal injury, 
within minutes. Vascular cells along with astrocytes and neurons are a part of a recently 
developed concept known as the Neurovascular Unit responsible for Neurovascular 
coupling (NVC), a phenomenon whereby an increase in neuronal activity leads to 
elevation of local CBF. The blood-brain barrier(BBB) chiefly composed of the vascular 
cells and astrocytes comprises the major role in NVC and thus is central to understanding 
brain functions and disorders. 
 Nitric oxide (NO) is a calcium-dependent vasoactive mediator that heavily 
influences NVC while intracellular calcium (Ca++) is a second messenger that serves for 
complex signaling roles in the brain. Impairment in the homeostasis of these signals can 
lead to extreme functional alterations in the brain. Furthermore, both NO and Ca++ 
changes have been shown to affect BBB permeability which is a common feature 
observed in many neurological disorders. Therefore, this research investigates the 
alteration of NO and Ca++ signals in the rat brain microvascular endothelial cells 
(BMVECs) and astrocytes, the two major cell types of BBB during inflammation, and 






signals by developing their co-culture model. It focuses on phenotypic and biochemical 
changes in BBB due to inflammation, as inflammation related failure of BBB is 
implicated in the initiation or progression of a wide variety of neurological disorders. 
Both NO and Ca++ were found to increase excessively in BMVECs unlike the astrocytes 
during inflammation, and in the co-culture model, the presence of astrocytes was found to 
provide negative feedback to these elevated NO and Ca++signals from BMVECs. 
Considering the dominant role of NO and endothelial cells in  NVC,  this research 
investigates a  potential application of a novel material, copper -cystine biohybrid known 
as Copper High Aspect Ratio Structures (CuHARS)  in catalyzing  NO in  BMVECs in 
normal as well as in induced inflammatory conditions. CuHARS was able to increase the 
NO concentration in normal BMVECs by stimulating endothelial nitric oxide synthase 
(eNOS) activity, known to have neuroprotective roles besides inhibiting the usually 
harmful NO synthesis in an inflammatory condition. Thus, CuHARS displays potential in 
therapeutic applications for NO related NVC disorders in addition to the antimicrobial 
and wound healing applications studied earlier. 
The tight junctions, unique to the endothelial lining of the brain, limit the entry of 
drugs against neurological and mental disorders from reaching into the brain. This poses 
an immense challenge in developing treatments for brain disorders. This research 
explores the naturally available Halloysite nanotubes (HNTs) for drug loading and 
delivery across the BBB. HNTs loaded with a fluorescent dye (RITC) and ionomycin 
separately were tested on BMVECs to study periodic and real-time attributes of HNTs in 
drug delivery. HNTs were found to deliver the payload gradually over an extended period 
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1.1 Background and Motivation 
Neurological disorders are reported to be the second leading cause of death 
globally after heart disease. They account for 16.5% of death, and are the leading cause 
of disability with 11.6% global disability-adjusted life year (DALYs) by the Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 which included studies 
from 1990 to 2016 for 195 countries (1).  Alzheimer’s disease, Epilepsy and seizures, 
Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), Brain Tumors, Multiple sclerosis, 
stroke, and headache are common neurological disorders.  The treatment of these and 
other diseases of the central nervous system (CNS) are rendered difficult by the 
physiologic, metabolic and biochemical obstacles, mainly the blood-brain barrier (BBB) 
and the blood-cerebrospinal fluid barrier (BCFB). The brain, being a crucial organ, has 
capillary microvessels which possess a unique feature termed as BBB that limits the 
influx and efflux of molecules and cells between blood and brain preventing the toxic and 
infectious agents circulating in the blood from getting into the brain (2,3). The 
endothelial cells of the brain are referred to as brain microvascular endothelial cells 
(BMVECs). They provide the relative impermeability of the BBB which results from the 
tight junctions and adherens junction between these cells formed by cell adhesion 





apposition of endothelial cells and astrocyte endfeet, with endothelial cells lining the 
luminal side and astrocyte endfeet wrapping around 99% of the abluminal side of the 
basement membrane in the BBB (4) as shown in Figure 1.1. The integrity of BBB allows 
it to control the brain homeostasis as well as ion and molecule movements, and disruption 
of BBB leads to cellular damage in neurological disease, including cerebral ischemia, 
multiple sclerosis, brain tumors, brain infection, and brain trauma (5).  
 
Figure 1: Schematics of blood brain barrier (BBB) showing features and 
orientation of cells involved in forming the BBB structure (6). 
Inflammation is the fundamental biological response of the body against injury 
and infection to remove the cause and effect of cell injury and to initiate cell repair, but 
chronic inflammation can lead to tissue damage and inappropriate immune response, 
unlike the beneficial acute response. Prolonged inflammation in the brain or CNS can be 
explicitly injurious and contribute to the pathogenesis of Alzheimer’s, Parkinson's, 





epileptogenesis (6,7). Neuroinflammation and BBB disruption are often related and are 
extensively being studied causes of a wide variety of neurological disorders (8–13). 
This research focuses on developing an in vitro co-culture model of the two major 
cell types of the BBB, BMVECs and astrocytes. The work and studies the inflammation-
induced morphological and signaling responses, specifically nitric oxide (NO) and 
intracellular calcium concentration (Ca++), in the monoculture and co-culture of these cell 
types to get a deeper insight on the phenotypical and biochemical response of endothelial 
cell-astrocyte interaction, which is expected to explain several aspects of BBB behavior 
in response to inflammation. In addition, this research also investigates the potential of 
the novel material Copper High Aspect Ratio Structures (CuHARS) (14,15) in altering 
the nitric oxide response during inflammation and normal physiological conditions in the 
BMVECs cells considering the significant role of NO in neurovascular coupling. 
The selective permeability of BBB imparted by the tight junctions of endothelial 
cells provides a natural defense mechanism against toxins and bacteria and prevents the 
drugs against neurological and mental disorders from crossing the barrier to reach the 
brain (16). Overcoming the BBB for drug delivery is a major challenge in the treatment 
of neurological and mental disorders, and the use of nanotechnology for the development 
of therapeutics against brain disorders has been attracting increasing research interest. 
Nanoparticles are versatile and promising drug delivery systems for inaccessible regions 
like the brain with the benefits of protection, encapsulation, and efficient delivery of 
therapeutic agents to the targeted area (17). Therefore, this research explores the potential 





1.2 Research Goals 
The phenotype of the blood-brain barrier is influenced by associated brain cells, 
specifically the astrocytic glial cells. These cells are involved in two-way 
communication. The close apposition of astrocytes to endothelial cells is thought to be 
necessary for the development and maintenance of the BBB junction proteins. The brain 
endothelium enhances the growth and differentiation of associated astrocytes while 
astrocytes release chemical mediators that modulate the barrier permeability over a time 
scale of seconds to minutes in addition to the long-term barrier induction and 
maintenance (14). Astrocytes occupy a strategic position between endothelial cells, and 
neurons and the endfeet that help form the BBB are especially involved in ionic, amino 
acid, neurotransmitter, and water homeostasis in the brain. Signals arising within the 
brain, rather than a programmed commitment of the endothelial cells, are known to be 
responsible for the expression of barrier properties (15). Therefore, this project aims to 
develop a co-culture model of primary brain microvascular endothelial cells (BMVECs) 
and astrocytes in vitro to study the cellular interaction in the BBB.  Specifically, the 
effect of co-culture on NO and calcium response is studied, as these are the signals that 
dominate in the brain during inflammation. The co-culture will also be tested for the 
toxicity, uptake, and delivery properties of novel materials such as CuHARS and 
biofriendly nanotubes-HNTs to investigate these particles as potential carriers for drug 






BMVECs produce excessive NO during inflammation and cellular interaction between 
astrocytes, and BMVECs provide negative feedback to this excessive NO produced by 
BMVECs. 
Hypothesis 2 
Copper High Aspect Ratio Structures (CuHARS) can increase NO release from BMVECs 
by catalytic action in the presence of S-nitrosocysteine (CysNO), an NO precursor found 
in the blood. This capacity for NO catalysis indicates its potential for therapeutic 
applications for brain conditions related to Neurovascular Coupling (NVC) disorder. 
Hypothesis 3 
Treatment of BMVECs with NO donor (sodium nitrite) in the presence of d-serine, a co-
agonist for glutamate receptor NMDA, enhances (Ca++) activity and causes calcium 
oscillations in the BMVECs. 
Hypothesis 4 
Inflammation leads to calcium dysregulation in BMVECs, and astrocyte cells can provide 
a negative feedback mechanism to the dysregulated calcium activity in BMVECs during 
inflammation. 
Hypothesis 5 
 Naturally available halloysite nanotubes (HNTs) can be a vehicle for targeted drug 
delivery across BBB for potential treatment of neurological disorders. 
1.3 Dissertation Overview 
Chapter 1 discusses the background and motivation for research, research goals, 





background and literature review on befitting research work involving cellular interaction 
between BMVECs and astrocytes, neurological disorders related to inflammation and 
BBB dysfunction, NO and Ca++ signaling in the brain, their physiological and 
pathological roles in the brain, and their respective role in BBB permeability. Chapter 3 
describes the technique of developing a mixed co-culture model consisting of BMVECs 
and astrocytes to mimic the BBB microenvironment and the characterization and 
evaluation of the coverage by each cell type in the co-culture model. Chapter 4 elucidates 
the role of astrocytes in providing negative feedback to the nitric oxide production in 
BMVECs during inflammation.  It underlines the NO production from individual cultures 
and from co-culture models while it highlights the morphological changes caused by 
inflammation in cellular networks. Chapter 5 addresses the application of copper-cystine 
biohybrid well known as CuHARS in catalyzing NO production from normal BMVECs 
in the presence of a NO precursor normally found in blood.  The chapter further explores 
CUHARS’ ability to alter NO produced by induction of inflammatory conditions in 
BMVECs. Chapter 6 discusses the effect of NO donor in calcium activity of the 
BMVECs cells and contemplates the role of astrocytes in modulating calcium 
dysregulation in BMVECs during inflammation by studying calcium activity in 
individuals and the co-culture model.  Chapter 7 presents the potential application of 
HNTs for drug delivery across the blood-brain barrier. Finally, Chapter 8 provides the 







BACKGROUD AND LITERATURE REVIEW 
 
2.1 Blood-Brain Barrier  
The blood-brain barrier (BBB), as the name suggests is a barrier between the 
brain’s blood vessels and the cells or other components that make up brain tissue. BBB 
has been identified as a complex and dynamic system involving biochemical and 
biomechanical signaling between the vascular system and the brain (20). The brain 
capillaries permeate the brain with a total length of approx. 600 km, total capillary 
surface area for membrane transport of  20 m2 and a mean transport distance of 40 µm.  
These dimensions suggest that almost every neuron in the brain is supplied with its own 
capillary (21). BBB constitutes the endothelial cells of the capillary wall, astrocyte 
endfeet that ensheath the capillary, and the pericyte cells embedded in the capillary basal 
membrane (22). These anatomic substrates of BBB constitute a neurovascular unit 
(NVU) which is central to neurovascular coupling (NVC) as shown in Figure 2.1. NVC 
is an essential phenomenon for the health and function of CNS. NVC is a relatively new 








Figure 2. 1: Schematic of a neurovascular unit. Left: The neurons and astrocytes are in 
close apposition to the endothelial cells.  Right: Neurovascular coupling highlighting 
energy exchange in between these cells (25). 
2.1.1 Brain Microvascular Endothelial Cells (BMVECs) 
The BMVECs are highly specialized cells.  The BBB requires such specialization 
because it is the major site of blood-CNS exchange (26) that maintains homeostasis of 
ions, nutrients, and other essential molecules for proper brain function (27). The presence 
of intercellular tight junctions and a thick continuous glycocalyx (a layer made of 
proteoglycans and sialoproteins that lines apical endothelium) along with the absence of 
fenestra, and a scarcity of pinocytic vesicles are unique characteristics of these cells that 
allow for the selective permeability between the systemic circulation and the extracellular 
fluid compartments in the brain (28). These features make BBB an effective organ for 
preventing unwanted substances such as toxins, bacteria, and other foreign materials in 
blood from accessing the brain, but it comes with a pitfall. It also prevents most potential 
drugs for neurological and mental disorders from readily crossing the barrier and 
reaching the brain, posing an immense impediment to the treatment of brain disorder. The 





While TJs seal the inter endothelial cleft AJs initiate and maintain endothelial cell to cell 
contact. Both junctions are composed of transmembrane proteins and cytoplasmic plaque 
proteins (29). Figure 2.2 shows the cell morphology of primary rat BMVECs cultured in 
vitro, depicting the feature of lumen which are the tubular structures formed in some 
endothelial cultures when they reach confluence. 
 
 
Figure 2. 2: A) Phase contrast image of in vitro culture of rat BMVECs showing 
morphology with characteristic lumen formation in between the cellular network B) 
DAPI stained image of BMVECs, networking to form a lumen C) Diff Quik 
stained image of BMVECs showing distinct nuclei and cell body of the cells. Scale 
bar= 100µm,Magnification =200X.  
2.1.2 Astrocytes 
Astrocytes (Figure 2.3) are the most abundant glial cells in the central nervous 
system, outnumbering neurons nearly fivefold  (30). Astrocytes occupy a strategic 
position in between neurons and capillaries and play a crucial role in ionic, amino acid, 
neurotransmitter, and water homeostasis of the brain specifically by the ones that form 
perivascular endfeet. The astrocyte endfeet are specialized processes that extend from 
its cell body to the basement membrane and surround the endothelial and pericyte 
cells. They cover the basement membrane surface area for a range of 80 to 99% of the 
CNS microvasculature. It also extends from the cell body to the neurons and thus 





coordinates blood flow with the neuronal activity (31). Factors secreted by astrocytes 
play an important role in the formation and maintenance of BBB by providing a requisite 
association between BBB cells and the formation of strong TJs (32). The proximity of 
endothelial cells to astrocytes suggests key roles of astrocyte-derived factors in BBB 
disruption and recovery after brain damage (4).  
 
 Figure 2. 3: Fluorescence microscopy image of rat astrocyte stained against the glial 
fibrillary acidic protein (GFAP) showing star-shaped astrocyte with multiple processes 
networking with surrounding cells. Scale bar=100 µm, Magnification =200X. 
2.2 Co-culture of BMVECs and Astrocytes 
The brain microvascular endothelial cells (BMVECs) differ from the endothelium 
of peripheral capillaries in the presence of complex tight junctions, absence of fenestra, 
limited pinocytic transport, and a continuous basement membrane that limits the 
permeability of molecules from the blood into the CNS (33). They also express a wide 
span of efflux pumps on their laminar surface that prevents the uptake of lipophilic 
molecules including drugs (34). Astrocytes provide signals for differentiation of the 
BMVECs and are essential in maintaining BBB integrity in vitro and in vivo (4,34). A co-
culture model of BMVECs with astrocytes provides an excellent technique to study 





may not accurately resemble the physiological relevance in the in vivo studies. The 
mixture provides a better insight into heterotypic cell-cell interactions (35). Moreover, 
astrocytes occupy a strategic position in between neurons and the capillaries and evidence 
suggests that signals from the brain, rather than a programmed commitment of BMVECs, 
are responsible for BBB properties (36). Astrocyte-derived factors are implicated in BBB 
disruption and recovery after brain damage. Vascular endothelial growth factor (VEGF), 
NO, glutamate, endothelin-1, and matrix metalloproteinases are astrocyte-derived 
vascular permeability factors that enhance BBB permeability and might lead to BBB 
disruption. In contrast,angiopoietin-1, glial-derived neurotrophic factor, retinoic acid 
insulin-like growth factor, and apolipoprotein E are the astrocyte-derived protective 
factors that can attenuate BBB permeability resulting in the recovery of BBB functions 
(4). Growing these two cell types together provides a characteristic morphological 
organization that is analogous to enzyme induction and tight junction comparable to in 
vivo (36). 
 Figure 2.4 illustrates a schematic diagram of BMVECs alone , and astrocytes 






Figure 2. 4: Schematic representation of A) normal rat brain astrocytes; B) 
endothelial cells (BMVECs); C) co-culture of normal rat brain endothelial cells and 
astrocytes. 
2.3 Neurological Disorder in Relation to Inflammation and BBB Dysfunction 
Diseases of the central and peripheral nervous system (PNS), which affect the 
brain, spinal cord, peripheral nerves, cranial nerves, nerve roots, autonomic nervous 
system, neuromuscular junctions, and muscles are defined as neurological disorders 
(37,38). Epilepsy, multiple sclerosis, ALS, stroke, and traumatic brain injury are some of 
the neurological disorders, each of which affects the CNS differently, but studies have 
suggested that they share common defects in the BBB (39). Disruption of BBB has a 
significant role in cellular damage in brain tumors, acute and chronic ischemia, brain 
infections, and neurodegenerative diseases. Inflammation is a biological response to 





acute inflammatory response is normally beneficial and ends at healing, but chronic 
inflammation can lead to tissue damage and inappropriate immune response (6). During 
inflammation, the changes at the BBB are mainly related to two-modes of action: 1) BBB 
disruption that describes the leakage and alteration of TJ components and ii) BBB 
activation, which implies the capacity of BBB cells to express and secrete immune 
factors that can influence the recruitment and effector functions and the survival of 
immune cells entering the brain (40). A cascade of molecular events during injury leads 
to an ultimate common pathway of BBB disruption caused by proteases and free radicals 
of oxygen and nitrogen that attack and degrade the tight junction proteins in BMVEC 
cells. These free radicals and proteases play a vital role in the early and delayed 
disruption of BBB as the neuroinflammatory response progresses. A compromised BBB 
contributes to cognitive changes in neurodegenerative diseases (5). Besides its crucial 
role in injury, the BBB as part of NVU plays an important part in angiogenesis, which 
helps in the recovery process. Therefore, identification of cellular and molecular events to 
prevent BBB disruption without hindering the recovery mechanisms is a major challenge 
in treating neurological disorders in addition to the usual course of facilitating drug 
delivery. 
2.3.1 Multiple Sclerosis (MS) 
MS is an ideal example of inflammatory disease of the CNS which is 
characterized by the destruction of the myelin sheath. MS is an autoimmune disease 
initiated by T- cells that attack the myelin which is escalated by the inflammatory 
response due to microglia and macrophages (6). Disruption of BBB and trans endothelial 





some of the earliest abnormalities seen in MS (12). Breakdown of BBB is thought to be 
transient in MS, though recurrence may be observed within weeks, months, or even 
years. The subsequent progression and lesion development in MS involves secondary 
phases of BBB leakage and demyelination mediated due to immune responses and 
various degrees of axonal injury (41). 
2.3.2 Alzheimer Disease (AD) 
AD is a widely recognized chronic progressive neurodegenerative disease. With 
pathological features of focal extracellular deposits of fibrillar amyloid β peptide (Aβ)  
and intracellular tangles of hyperphosphorylated tau proteins in the brain, it also causes 
dementia (42,43). Pathogenesis of this disease involves interaction with immune 
mechanisms in the brain with an elevation of inflammatory cytokines, acute-phase 
proteins, and complement components along with signs of activated microglia and 
astrocytes locally in the regions where Aβ deposits as foci (6). Reduced expression of TJ 
proteins, reduction in capillary length suggesting endothelial degeneration, and capillary 
basement membrane changes have been reported from brain tissue of patients with AD. 
Dysregulated intracellular [Ca++] homeostasis and BBB damage have been implied in the 
pathogenesis of AD (44). 
2.3.3 Parkinson’s Disease (PD) 
PD is the second most prevalent neurodegenerative disease, with pathologic features of 
progressive death of dopaminergic neurons in the substantia nigra (midbrain region that 
modulates motor movement and reward functions) and intracellular accumulation of α-
synuclein protein-rich Lewy bodies. PD is a multisystem disorder and neuroinflammatory 





neurovascular dysfunction which in turn is an important pathway leading to loss of 
dopaminergic neurons (45). Disruption of BBB increases the susceptibility of neurotoxic 
substances to dopaminergic neurons and immune system mediators that contribute to PD 
progression (46). 
2.3.4 Epilepsy 
Epilepsy is the fourth most prevalent neurological disorder characterized by 
recurrent and unpredictable seizures that might be caused by brain injury or heredity (47). 
BBB disruption encourages seizures, favors seizure recurrence, and contributes to 
epileptogenesis. The electrophysiological viewpoint suggests that BBB disruption results 
in serum albumin penetration to the brain, loss of water, and dysregulation of glutamate 
and potassium, ultimately altering the brain microenvironment and neuronal functions 
(48). During inflammation leukocyte binding at the endothelium initiates BBB 
dysfunction, which causes increased permeability to ions and proteins, edema, and 
changes in the brain microenvironment. Proinflammatory stimuli are indicated to cause 
seizure promoting communication between the periphery and brain. Inflammatory 
stimuli, including lipopolysaccharide (LPS), upregulate monocyte chemotactic protein 
which causes an increase in BBB permeability (49).  
2.3.5 Amyotrophic Lateral Sclerosis (ALS) 
ALS is a neurodegenerative disease that results in progressive loss of motor 
neurons, thus causing muscular paralysis and death mostly within 2-5 years of diagnosis 
(50). ALS occurrence is mostly implied to a composite syndrome with irregular 
pathways, but neuroinflammation is a major facet of ALS pathology(50). Activation of 





cells and T cells enhance cytokine production that facilitates the entry of immune cells, 
including the mast and T cells themselves, when the barrier integrity is compromised. As 
is seen in other neurodegenerative diseases, oxidative stress-induced reactive free radicals 
at brain endothelial cells can cause a hyperpermeable BBB that allows a wider range of 
molecules to pass through, resulting in a more dreadful and faster progression of ALS 
disease (51).  
2.3.6 Traumatic Brain Injury (TBI) 
TBI is defined as the disruption in normal brain function, possibly caused by a 
blow, bump, or jolt to the head, or penetrating head injury (52). While mild TBI may 
cause only temporary dysfunction, severe injury can cause bruising, bleeding, damaged 
tissues, and other physical insults to the brain followed by secondary pathological 
progressions such as ischemia, neuroinflammation, and excitotoxicity that might lead to 
long term complications or death (53). In both the adult and the developing brain, one of 
the first responses to injury is the degranulation of mast cells which might facilitate the 
BBB breakdown (54). Growing evidence suggests that the ischemic, hemorrhagic, or 
traumatic brain injury leads to BBB breakdown which is thought to be responsible for the 
death of neural tissue and to affect response to neuroprotective drugs. Brain inflammatory 
response to injury is a significant part of TBI pathophysiology. There is an upregulation 
of proinflammatory cytokines like TNFα and IL1- β followed by increased release of 
chemokines and cell adhesion molecules on an endothelial surface that increases leakage 





2.3.7 Cerebral Ischemia 
Cerebral ischemia refers to a lack of oxygen supply in the brain, caused by 
blockage in an artery, that leads to damage of brain tissues (56). It is responsible for 80% 
of the total strokes, where the rest (20%) are due to cerebral hemorrhage. Stroke (a form 
of cerebral ischemia) is the most frequent cause of disability, the second most common 
cause of dementia, and the fourth most common cause of death in first world countries 
(57). Pathology of stroke is characterized by inflammatory responses like microglial 
activation, cytokine or chemokine release, and neutrophils and macrophages infiltration 
(58). Activation of mast cells is another important feature of ischemic injury. Ischemia is 
accompanied by BBB breakdown, allowing for immune-inflammatory cell influx into the 
brain. Mast cells occur on the brain side of BBB and enhance its breakdown. Further, 
BBB disruption can result in alteration of hyperpermeability and extravasation of 
leukocytes into brain tissue, resulting in edema formation in neuropathological disorders, 
including stroke (59). 
It is obvious from the above descriptions of the variety of neurological disorders 
that research relating to inflammation and BBB disruption had been biased against the 
role of microglia and astrocyte during brain inflammation while endothelial cells, though 
being a major part of NVU and the BBB have been left out by most of the studies. 
Therefore, this research attempts to fill the gap of information related to inflammatory 
changes in the BMVECs and the effect of their cellular interactions with astrocytes in the 





2.4 Cell Signaling Molecules 
The molecules that help the cells communicate between or within themselves are 
known as cell signaling molecules. Though typically these molecules act as ligands that 
bind to the receptors expressed by target cells, a large variety of structurally and 
functionally different types of molecules serve in cell signaling. Structurally they range 
from simple gases to proteins. Some molecules carry the signal over long distances and 
are called endocrine signals, while some act locally to affect the behavior of surrounding 
cells and are called paracrine signals. Some major types of signaling molecules are 
discussed below. 
2.4.1 Hormones 
Hormones are major endocrine signaling molecules, which come in two varieties. 
i) Steroid hormones are lipid-soluble molecules that interact with receptors in 
the cytosol or nucleus of cells such as estrogen and progesterone. 
ii) Peptide hormones are water-soluble molecules that bind to cell surface 
receptors such as insulin, growth factors, and glucagon. 
2.4.2 Gaseous Molecules 
2.4.2.1 Nitric Oxide (NO) 
NO is a gaseous molecule and is a major paracrine signaling molecule in the nervous, 
circulatory, and immune system of body.  NO diffuses freely across the plasma 
membranes of the target cells like the steroid hormones, however its mode of action is 
different in that it acts directly on the intracellular target enzymes rather than binding to 
the receptors that regulate transcription. NO is synthesized by an enzyme nitric oxide 





NOS, constitutive (cNOS) and inducible (iNOS), synthesize NO during normal 
physiological conditions and inflammation respectively. A third form of NOS, neural 
NOS (nNOS) acts as a neurotransmitter in the CNS and peripheral nervous system (60). 
Though NO is produced under physiological condition through oxidation of L-arginine, 
L-arginine is not a limiting factor for the reaction, as NO can be synthesized from 
citrulline or glutamic acid, but when iNOS is active for a long time, L-arginine becomes 
depleted, causing iNOS to produce superoxide anion (O2-) (61). 
NO is a key signaling molecule in the dilation of blood vessels. The process 
initiates after the release of neurotransmitters like acetylcholine from the nerve terminals 
in the wall of blood vessels. These neurotransmitters stimulate NO synthesis from the 
endothelial cells that diffuse to nearby smooth muscle cells (SMCs) as shown in Figure 
2.6, where it acts on the enzyme guanylyl cyclase to increase the second messenger cyclic 
GMP (guanosine monophosphate) that induces SMCs relaxation and thus results in vessel 
dilation (62). 
 








Figure 2. 6: NO signaling pathway for blood vessel dilation between endothelial and 
smooth muscle cells. R : Receptor, L-arg :L-arginine, cNOS: constitutive nitric oxide 
synthase, GC: Guanylyl cyclase, GTP: guanosine triphosphate, cGMP: cyclic 
guanosine monophosphate(60). 
2.4.2.2 Carbon monoxide (CO) 
Carbon monoxide (CO) is another gaseous molecule that functions as a signaling 
molecule in the nervous system. Like NO, it’s synthesis in the brain is also stimulated by 
neurotransmitters, and it also acts as a mediator for vasodilation (62). 
2.4.3 Neurotransmitter 
Neurotransmitters are the chemical messenger that carry signals between neurons 
or between neurons and other target cells across chemical synapses such as muscles. The 
size of a neurotransmitter varies from a single amino acid to large proteins or peptides. 
Neurotransmitters constitute a great variety of hydrophilic molecules such as glutamate, 
γ-aminobutyric acid (GABA), dopamine, epinephrine, serotonin, histamine, and glycine 
(64). Classical neurotransmitters are packaged and stored in synaptic vesicles once 
synthesized by the presynaptic neuron. Neurotransmitters are released at the synaptic 
cleft when the threshold action potential is reached (65, 66), where they bind with 






Figure 2. 7: Neurotransmission at the synaptic cleft between the presynaptic and 
postsynaptic neurons (67). 
2.4.3.1 Glutamate 
Glutamate is the most abundant free amino acid and the main excitatory 
neurotransmitter in the brain. It is the principal mediator of nervous system plasticity and 
is at the crossroad of multiple metabolic pathways (63,65). It is implicated to be vital in 
modifying synapses that are believed to be essential for learning and memory.   
Glutamate is able to elicit cell death through its unregulated excitatory effect on neurons, 
and the process is referred to as excitotoxicity. Glutamate uptake systems strongly 
dominated by astrocytes prevent excessive activation of glutamate receptors by 
continuous removal of glutamate from the extracellular fluid in the brain. Moreover, the 
BBB defends the brain from glutamate in the circulating blood (66). Most of the cells in 
the nervous system express at least one of the several types of glutamate receptors  (68). 
Glutamate receptors have been classified as N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate receptors, and 





influx is one of the major causes of excitotoxicity (69,70), which is implicated in epilepsy 
and some neurodegenerative diseases like AD, PD, and Huntington’s disease (71–73). 
2.4.3.2 GABA 
GABA accounts for about 40% of the inhibitory processing in the brain and 
therefore serves as a major inhibitory neurotransmitter in the brain. Its primary function is 
to reduce neuronal excitability throughout the nervous system (64). 
2.4.4 Cytokines 
Cytokines are small proteins secreted by cells that help in cellular interactions and 
communications in the immune system. Interleukins (cytokines made by leukocytes that 
act on other leukocytes), chemokines (cytokines with chemotactic activities), 
lymphokines (cytokines made of lymphocytes), and monokines (cytokines secreted by 
monocytes) are the different classes of cytokines. They might be autocrine, paracrine, or 
endocrine in function. There exist both proinflammatory and anti-inflammatory 
cytokines. Proinflammatory cytokines such as IL-1β, IL-6, and TNF-α are released 
primarily by activated macrophages and assist in up-regulating the inflammatory 
reactions (74).  
TNF-α, also identified as cachectin, is produced mainly by macrophages or 
monocytes during inflammation, which makes up the acute phase reaction, but if 
unchecked, it can elicit chronic and acute diseases that may be both infectious and non-
infectious (75). TNF is primarily responsible for regulating immune cells and it can 
induce fever, inflammation, cachexia or apoptotic cell death. It can also inhibit 
tumorigenesis, viral replication, and sepsis via IL-1and IL-6 releasing cells. TNF is 





(LPS), an endotoxin from bacteria (76). TNF dysregulation has been implied as a 
hallmark of acute and chronic neuroinflammation along with many neurodegenerative 
diseases such as AD, PD, ALS, MS, and ischemic stroke (77).  
2.5 Nitric Oxide Signaling in Brain 
2.5.1 Physiological Roles of NO 
NO plays a vital role in intracellular signaling in neurons from modulating 
neuronal metabolic status to dendritic spine growth, serving as the retrograde 
neurotransmitter in brain synapses and regulating cerebral blood flow. Further, it is also 
an important player in regulating protein functions, as it can execute post-translational 
modification in proteins by S-nitrosylation of thiol amino acids (61,78). S-nitrosylation of 
proteins is a secondary pathway by which NO can influence CNS neurotransmission (79). 
The significance of NO as a neuromodulator or an intermediary signal in the brain is 
underlined by the fact that glutamate, the most abundant amino acid in the brain and the 
excitatory neurotransmitter, is an initiator of the reaction that produces NO (78,80). As 
seen in Figure 2.8, glutamate, when released in synapses, activates the NMDA receptors 
allowing Ca++ influx in the postsynaptic neurons, which activates nNOS, producing NO. 
Thus released NO acts on presynaptic neurons (retrograde neurotransmission) where it 
stimulates the release of GC-independent mechanism of glutamate exocytosis from a 
presynaptic neuron which results in long term potentiation (LTP), the physiological 
mechanism of learning and memory (61,81,82).  LTP induces the dendritic spine growth 
by activating cAMP-response element-binding protein (CREB), which activates the gene 






Figure 2. 8: NO signaling pathway as retrograde neurotransmitter and facilitator of 
LTP (61). 
2.5.2 Pathological Roles of NO 
Though NO serves a wide variety of physiological roles, it can be harmful and 
toxic to the brain during pathological processes and aging when it reacts with free 
radicals like O2- to form peroxynitrite (ONOO−). Peroxynitrite is formed when NO reacts 
with O2- and is a vigorous oxidant that results in a broad variety of tissue-damaging 
effects such as enzyme and ion channel inactivation. The inactivation occurs due to  
protein oxidation or nitration, lipid peroxidation, and inhibition of mitochondrial 
respiration by peroxynitrite (82).  O2- can easily diffuse throughout the membrane and 
damage proteins, lipids, and nucleic acids of neurons. In proteins, it mostly reacts with 
the tyrosines to form nitro-tyrosines which affect the physiological functions of proteins 
dramatically and irreversibly. This phenomenon of protein nitrotyrosination leads to the 
agglomeration of modified proteins contributing to the initiation and progression of 





 NO has a dual role in the immune system. Under physiological condition, NO is 
anti-inflammatory as it impairs leucocyte influx through the capillary walls preventing 
inflammation and working as an immune brake (83), but in both adaptive and innate 
immune response, leukocyte activation leads to iNOS expression and the NO produced 
contributes to inflammatory reactions by regulating cytokine release (84). NO regulated 
inflammation is highly relevant in the brain as microglia, astrocyte, and endothelial cells 
(85, 86),  are found to express iNOS. Neuroinflammatory responses drastically increase 
the risk of neurodegenerative diseases as was discussed in Section 2.3.  
Moreover, the increase in NO caused by higher iNOS expression during 
inflammation amplifies the chances of nitration. The brain has a high amount of 
unsaturated lipids that serve as targets for oxidation and peroxidation, which makes it 
susceptible to oxidative and nitrative damage that tends to increase with aging. AD and 
PD exhibit the highest etiopathogenic relationship with nitrative stress (86–88) while MS, 
ALS, and Huntington's disease show close association to oxidative stress and protein 
nitrotyrosination (89–91). Because NO acts as a double edge sword through its numerous  
physiological and pathological roles, it has a significant association in clinical medicine 
and thus opens up new therapeutic opportunities (80).  
2.5.3 NO and BBB Permeability 
The selective permeability of BBB prevails due to the expression of multi-drug 
resistant gene (MRD1) and multi-drug resistant associated proteins in the endothelial 
cells, in addition to its unique features of presence of tight junctions, absence of fenestra, 
and scarcity of pinocytic vesicles. NO has been implicated by many studies to mediate 





damage, though the precise molecular mechanism is not clearly understood (28,92).  
Evidence from in vivo studies has suggested that NO itself can mediate a moderate 
disruption in BBB but the disruption is greatly enhanced when treated with NO donor 
producing several redox species of NO (93). The NO released from eNOS is thought to 
have a protective effect because it is a vasodilator in BMVECs, but NO produced from 
iNOS is a fraction of the biochemical cascade activated by inflammation or injury and 
has been implicated in altering BBB integrity (94,95). The cytokines TNF, IL-1β, 
interleukin-6, and interferon-γ, all of which induce expression of iNOS, have been shown 
to modulate BBB integrity (94,95). The high volume of blood flow and exchange in 
blood vessels makes them more prone to generate free radicals of NO and O2-, which can 
react to form (ONOO−) under pathological conditions like injury and stroke, thus leading 
to oxidative damage of proteins, lipids, and DNA at the BBB and further induce toxicity 
through nitrosylation of proteins (92). The NOS inhibitor NG‐nitro‐L‐arginine methyl 
ester [L‐NAME] was found to inhibit the activation of matrix metalloproteinases (MMPs) 
in rat ischemic models. MMP activation is a critical pathway for BBB opening as it can 
hydrolyze TJ proteins and BBB extracellular matrix, leading to BBB opening (96,97). 
Thus, those studies suggested NO mediated BBB opening through activation of MMPs. 
2.6 Calcium (Ca++) Signaling  
Ca++ impacts almost all aspects of cellular life. It is the simplest and yet most 
versatile second messenger in biology (98). Second messengers are the molecules that 
transmit the signal received at cell surface receptors like growth factors, cytokines, 
neurotransmitters, and proteins. The functions of proteins are driven by their shape and 





ability of Ca++ to change the local electrostatic field and protein conformation is a 
ubiquitous tool of signal transduction (99). The Ca++ gradient is maintained at 10,000-fold 
higher outside the cells compared to cytosolic free Ca++ inside the cells (100). The vast 
difference in the gradient controls the underlying speed and effectiveness of Ca++. The 
dramatic Ca++ changes within a cell are induced by voltage-dependent Ca++ selective 
channels (VDCCs) which are the fastest Ca++ signaling proteins. Each VDCC can 
conduct almost a million Ca++ ions/second down the 10000- fold gradient, and about a 
few thousand channels can cause more than 10 fold changes in intracellular Ca++ levels 
within milliseconds (101).  
Calcium signaling in cells occurs either through the gap junctions (connexin 
channels) present in epithelia and cardiomyocytes or through transmitter-gated, ion 
channels such as NMDA, nicotinic, and purinergic receptors. These transmitter-gated or 
voltage-gated channels are a more common pathway of calcium signaling that can rapidly 
increase periplasmic Ca++.  This increase stimulates proteins that enables transmitter-
containing vesicles to fuse to the plasma membrane and release molecules such as 
glutamate, adenosine triphosphate (ATP), and acetylcholine, outside the cells onto 
adjacent cell membranes (102). These calcium moderated events dominate most of the 
neuroscience and are now appreciated in all cell types for extracellular communication 
(99). 
2.6.1 Calcium signaling in the Brain 
Ca++ has a fundamental and versatile role in neuronal plasticity. It is a second 
messenger for many signaling pathways in the brain such as energy production, neuronal 





survival, and processes central to learning and memory (103). Ca++ influx in neurons is 
regulated by VDCCs, NMDA receptors, or transient receptor potential (TRP) channels 
located in the plasma membrane. In addition, inositol-1,4,5-triphosphate receptors 
(IP3Rs) and ryanodine receptors can increase Ca++ level by mediated release from Ca++ 
stores in endoplasmic reticulum (ER) or sodium-dependent Ca++ efflux from 
mitochondria (104). Mitochondrial Ca++ controls ATP synthesis by regulating three Ca++ 
sensitive dehydrogenases (pyruvate dehydrogenase, isocitrate dehydrogenase, 
oxoglutarate) of the citric acid cycle. Besides, it shapes the spatiotemporal patterns of 
Ca++ signals and is central in determining cell death and survival (105). Ca++ from ER 
controls a wide range of neuronal functions, from excitability of plasmalemma to 
synaptic plasticity and modification of protein synthesis (106). The NMDA receptor, 
upon binding to glutamate, permeates Na+ and Ca++.  Na+ contributes to postsynaptic 
depolarization while Ca++ causes Ca++ transients and ultimate physiological response. 
The Ca++ influxes through NMDA or glutamate receptors are responsible for regulating 
CREB dependent gene transcription (107) which is physiologically relevant to 






Figure 2. 9: Neuronal calcium signaling, showing sources of calcium influx and 
efflux from the cell. Sources: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) and N-methyl-D-aspartate (NMDA) voltage-gated calcium 
channels (VGCC), nicotinic acetylcholine receptors (nAChR), and transient receptor 
potential type C (TRPC) channels. Mediators for calcium release from internal 
sources inositol trisphosphate receptors (IP3R) and ryanodine receptors (RyR), 
metabotropic glutamate receptors (mGluR). Mediators of Ca++ efflux : plasma 
membrane calcium ATPase (PMCA), the sodium-calcium exchanger (NCX), and the 
sarco-/endoplasmic reticulum calcium ATPase (SERCA) metabotropic glutamate 
receptors (mGluR) (107). 
As Ca++ plays a central role in neuronal physiology, even a slight alteration of 
Ca++ homeostasis results in extreme functional alteration. Disruption of Ca++ homeostasis 
is indicated in neurodegenerative and neuropsychiatric diseases, and normal aging 
process despite their heterogeneous etiology(103). 
2.6.2 Pathological Roles of Ca++ in Brain 
Ca++ ion has been chosen as major intracellular signaling by evolution, possibly 
from the moment when ATP came to be known as an energy substrate (108). During 
aging and in neurodegenerative diseases, the mitochondrial aberration is related to 





Evidence supports that crosstalk between Ca++ and redox signals play important roles in 
brain physiology, but the redox signal promoted by oxidative and nitrosative stress causes 
excessive Ca++ release and provokes a pathological response and neuronal death 
(111,112). The high O2 consumption (~20% of O2 consumption in the body) of the 
nervous system makes it prone to large quantities of reactive oxygen species (ROS) 
formation. These species make it sensitive to oxidative stress caused by the enrichment of 
unsaturated fatty acids in nerve cell membranes. Ca++-dependent pathways regulate the 
components of ROS homeostasis (113). Also, Ca++ stimulates  NO synthase that has been 
shown to induce ROS generation during oxidative stress (105). ROS mediated oxidation 
of nitrosium ions (NO+) releases RyR mediated Ca++ from the ER (114). 
Ca++ dependent synthesis of free radicals was observed in response to β-amyloid (Aβ) 
indicated for causing AD (115), and also was shown to be induced in neuronal death after 
ischemia (116).  
Neurodegenerative diseases, despite exhibiting a wide range of heterogeneity in 
their appearance, show a prominent similarity in the molecular pathogenesis, as all of 
them feature dysregulation in Ca++ homeostasis and signaling that involves alteration in 
Ca++ regulating proteins through excitotoxicity, perturbed energy metabolism, alteration 
in Ca++ buffering capacity, dysregulation of Ca++ channel activities, and oxidative stress. 
Ca++ dysregulation can trigger cell death by activating proteases, caspases, or other 
catabolic processes mediated by nucleases and lipases (105,117). Apart from 
neurodegenerative diseases such as AD, PD, MS and ALS (118–121) disturbance in Ca++ 
homeostasis leads to many other neurological diseases such as epilepsy, peripheral 





and schizophrenia (122–125). Changes in Ca++ signaling pathways have also been 
identified that underlie the progression of biological markers of aging (126,127). 
2.6.3 Calcium and BBB Permeability 
Permeability of BBB is principally governed by the TJs between endothelial cells, 
and both high and low calcium levels have shown adverse effects on the cell to cell 
contact of endothelial cells (128,129).   
Ca++ activities affect migration of ZO-1tight junction protein from intracellular 
sites to the plasma membrane (130), tight junction assembly (131), and electrical 
resistance in endothelial and epithelial cells. Particularly, Ca++ regulation plays a central 
role in TJ disruption between endothelial cells leading to an alteration in BBB 
permeability (132–135). A decrease in Ca++ alters ZO-1-acting binding and changes the 
intracellular localization of occludin whereas an increase in intracellular Ca++  interferes 
with TJ formation (131). Vasoactive agents such as histamine, endothelin, bradykinin, 
and nucleotides such as ATP, adenosine diphosphate, and uridine triphosphate that are 
known to increase BBB permeability also show calcium elevation (136,137). These 
pieces of evidence suggest that Ca++ regulation in BMVECs is critical in moderating 
BBB permeability. 
Disruption of BBB is a key element in the pathogenesis of neurodegenerative and 
neurological disorders, including epilepsy, stroke, AD and PD. Moreover, the capacity to 
cross the BBB is a major consideration for targeted drug delivery in the brain. In vivo, 
optical imaging in rat cerebral cortex showed that glutamate release, which is mostly 
controlled by the Ca++ entry in neurons, increased vascular permeability which was 





(138–140) as do neuron, astrocytes, and microglia. As shown in Figure 2.10, the 
activation of these endothelial NMDA receptors by glutamate produces a Ca++ influx that 
results in Ca++ dependent NOS activation and thus NO release (141–143). Thus released 
NO activates GC in endothelial cells to generate cGMP and increased levels of 
intracellular cGMP results in a signaling cascade that leads to BBB opening by 
rearranging TJ proteins away from cell-cell contact regions (141). Besides microglia can 
also be activated by glutamate via NMDA receptors leading to NO production that might 
further be activated following BBB opening thus creating positive feedback for BBB 
disruption (144). 
 
Figure 2. 10: A  proposed mechanism for glutamate-induced BBB disruption by 
Vazana et al. (2016) displaying that glutamate released from neurons can act on 
endothelial cells via NMDA receptors on them to include Ca++ dependent NO release 
leading to BBB opening (141). 
Calcium modulates numerous downstream processes like protein phosphorylation 
via protein kinase C (PKC) and ROS generation, both of which can regulate protein 






2.7.1 MTT Assay 
MTT assay is used to evaluate the metabolic activity of the cells. As shown in Figure 
2.11, the yellow-colored MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] is reduced to non-water-soluble purple formazan crystals in living cells. The 
purple-colored crystals are dissolved in an organic solvent and converted into a colored 
solution. The formazan products are then quantified using spectrophotometry at 595 nm. 
The reduction of MTT provides a measure of cellular metabolism that correlates to 
cytotoxicity. MTT can be reduced to formazan product only by the metabolically active 
cells (145,146). 
 
Figure 2. 11: Reaction scheme for MTT reduction (147). 
2.7.2 NO Assay 
The indirect determination of NO involves the spectrophotometric measurement of its 
stable decomposition products NO3− and NO2−. This technique requires NO3− to be 
reduced to NO2− first and then NO2− is quantified by using Griess reaction as shown in 
Figure 2.12. Briefly, the Griess reaction is a two-step diazotization reaction in which the 





catalyzed formation of nitrous acid from nitrite (or autoxidation of NO) reacts with 
sulfanilamide to produce a diazonium ion which is then combined with N-(1-naphthyl) 
ethylenediamine to produce a chromophore (azo product) that absorbs strongly at 540 
nm. For quantification of NO3− and NO2− in extracellular fluids, the enzymatic reduction 
of NO3− to NO2− using a commercially available preparation of nitrate reductase is a 
satisfactory method.  
 
Figure 2. 12: The dinitrogen trioxide (N2O3), nitrosating agent generated from 
acidified nitrite (autooxidation of NO) reacts with sulfanilamide to yield diazonium 
derivate, which will interact with N-(1-naphthyl) ethylenediamine to yield a colored 








DEVELOPMENT OF A CO-CULTURE OF PRIMARY 
BMVECS AND ASTROCYTES AS A MODEL OF THE 
BLOOD BRAIN BARRIER 
 
3.1 Introduction 
The brain is the center for an array of diverse physiological activities in the body 
and it integrates signals received from the external environment with those from the 
internal environment at the neuronal level to execute specific functions. The chemical 
environment in which the brain cells operate needs to be strictly regulated which is the 
fundamental function of the blood-brain barrier.  The endothelial cells (BMVECs) line 
the luminal side of the brain capillaries while the abluminal side is completely wrapped 
around by a basement membrane, 99% of which is covered by the astrocytic end feet. 
Evidence suggests that the direct contact between endothelial cells and astrocytes is at 
least partially responsible for the development and maintenance of tight junctions 
between the endothelial cells of BBB (107). The close apposition of astrocytes to 
endothelial cells makes them an important participant of morphological homeostasis by 
helping in the formation of BBB. Further astrocyte-derived factors such as NO, vascular 
endothelial growth factor (VEGF), glutamate, endothelin-1 and matrix metalloproteinase 
have been known to enhance BBB permeability, leading to its disruption, while 
angiopoietin-1, glial-derived neurotrophic factor, retinoic acid, insulin-like growth factor, 





A co-culture model provides us with a propitious system to study cell to cell 
interaction between a different population of cells in vitro. Most of the models studying 
BBB permeability consists of a monolayer of endothelial cells, but often when cultured 
alone, the endothelial cells once isolated from brain capillaries begin to lose their BBB 
characteristics.  Given this, we aim to develop a co-culture model of primary brain 
endothelial cells and astrocytes to closely mimic the BBB microenvironment and study 
the cellular interaction in between them and subsequently investigate the role of 
astrocytes in providing a negative feedback mechanism to the two major signaling 
molecules, NO and Ca++ when inflammation is induced in the BBB. 
3.2 Materials and Methods 
3.2.1 Cell Culture 
Pregnant Sprague Dawley rat pups were sacrificed by cervical disarticulation between 
post-natal day 1 – 3.  All procedures were conducted according to a protocol approved by 
the Louisiana Tech University Animal Care and Use Committee. Rat brain cortex was 
obtained by dissecting the skull and moving it into a petri dish containing Basal Media 
Eagle (BME, Sigma Aldrich) with 0.5% Penicillin Streptomycin (Sigma), where the 
cerebellum, olfactory lobe, and meninges were removed. The cortical lobes were 
collected in an F12 nutrient mixture containing 10% fetal bovine serum, 10% horse 
serum, and other components  (heparin, glutamine, NaHCO3)  and stored on ice until 
cortical tissue is obtained from an average of 7 pups. The cortical tissue is then aspirated 
into a 15 ml tube consisting of astrocyte medium with  Ham’s F-12K medium containing 
5% Horse serum and 5% FBS (Appendix C.4) with a complementing volume of Trypsin 





least 5 times and incubated for 10 minutes at room temperature. The media with trypsin 
was pipetted out and fresh astrocyte media was added to the tissue. The tissues were then 
mechanically dissociated by triturating 15 to 20 times and incubated for 10 minutes to 
form a brain cell supernatant. This whole process of adding trypsin and then triturating is 
repeated at least three times and each time the brain cell supernatant was collected and 
stored in a 15 ml tube in an ice bath, which was then centrifuged to get a pellet of cells. 
The cells were then cultured in a cell culture flask to get primary glial cell culture. 
 BMVECs were isolated from this primary culture by treating them with 5.5 μM of 
puromycin dihydrochloride that kills all other cell types except the endothelial cells. 
Endothelial cells are encoded with a puromycin N-acetyl transferase gene (PAC gene), 
which confers resistance to the action of puromycin (28,144). Thus, isolated BMVECs 
were then cultured in vitro at 5% CO2 and 37 °C in a rat endothelial growth medium (Cell 
Applications Inc.) (Appendix C.3). Astrocytes were purified from the glial culture by 
sub-culturing these cells and washing off the overlaying microglial cells a few times 
before they are sub cultured. 
3.2.2 Cell Characterization 
The BMVECs were characterized by staining them against Von Willebrand 
Factor (VWF), (Appendix G.3, Figure 3.2), an essential blood-clotting protein specific 
to endothelial cells, and astrocytes were characterized by staining them against the glial 
fibrillary acidic protein (GFAP), a cytoskeletal protein found specifically in glial cells. 





3.2.3 Co-Culture Model 
Primary BMVECs and astrocyte were plated at a density of 20,000 cells each well 
at the ratio of 1:1 in their respective growth media into the same well with direct cell-cell 
contact in a 48-well cell culture plate (Greiner) and incubated at 5% CO2 and 37 °C for 
about 6-8 days until the confluency of cells in the wells reach ~ 80%. 
3.2.4 Cell Fixation 
After 6-8 days in vitro, the growth medium from the cells was aspirated and 
washed with 300 µl of RPMI (Appendix F). To fix the cells, 250 µl of the 1X solution of 
fixative was added such that it covered the entire well, and the plate was kept at room 
temperature for 10 minutes. The cells were rinsed twice with 500 µL 1X PBS again. 
3.2.5 GFAP Staining 
To confirm normal in vitro characteristics and visualize cellular network in direct 
contact between endothelial cells and astrocytes, astrocyte cells in the co-culture model 
were stained using indirect immunofluorescence for glial fibrillary acidic protein 
(GFAP). Cells were stained using Anti-Glial Fibrillary Acidic Protein (Anti-GFAP), an 
antibody produced in the rabbit as 1° Ab from Sigma-Aldrich (Sigma Product #G9269), 
and Alexa Fluo® 488 goat anti-rabbit IgG (H+L) as 2° Ab from Invitrogen Molecular 
Probes (Invitrogen Product #A-11035) (Appendix G.4). 
3.2.6 DAPI Staining 
Nuclei for all cells were stained with 4,6-diamidino-2-phenylindole (DAPI) to 
confirm cell viability and to visualize and identify the networks of astrocytes stained 







Microscopic images of the cells were recorded under a Leica DMI 6000B inverted 
microscope. Phase-contrast images of the co-culture cellular networks were obtained to 
identify morphological characteristics of each cell type in the direct contact network 
which was followed by recording GFAP images of the cell culture model. GFAP staining 
was viewed under fluorescence settings. For fluorescent imaging, a Leica EL6000 light 
source was used. For GFAP imaging, excitation in the blue portion of the light spectrum 
(~475 nm) was required. To view DAPI-stained nuclei, excitation light in the ultraviolet 
range (~400 nm) was required. GFAP emits green light and DAPI emits blue light. 
3.2.8 Image Analysis 
The GFAP images captured through digital microscopy for the co-culture model 
were analyzed using Image Pro-Plus version 7.0 developed by Media Cybernetics 
(Rockville, MD). A mask was created to select the area covered by astrocytes on each 
captured image from the co-culture model, as shown in Figure 3.1 and described in the 
protocol (Appendix B). The area of the astrocyte cells present per image was analyzed 
and saved to Microsoft Excel. The data thus obtained were used to compute the total area 
covered by astrocytes per image, averaged over 3 images each well for 2 experiments 







Figure 3. 1: Masking of image and measuring area covered by astrocytes in the co-
culture model using Image Pro 7 software. 
3.2.9 Statistical Significance 
A one-way ANOVA was generated with the multiple comparison method for 
experiments consisting of more than two groups, and two-tailed t-tests were used to 
compare two groups. The results were considered statistically significant when P < 0.05. 
Data are presented as the mean ±standard error of the mean (SEM).  
3.3 Results 
3.3.1 Von-Willebrand Factor (VWF) Staining 
To determine the purity of isolated BMVECs culture obtained from primary glial 
culture, the cells were stained against VWF, a biomarker for endothelial cells (Figure 
3.2). The cells were treated with primary and secondary antibodies as described by 
protocol (Appendix G.3), and images were captured through digital microscopy after 
staining. The images showed 100% staining of the culture, as shown in Fig 3.2B, 
indicating the high purity of the culture, while the negative control cells (treated with 
secondary but not the primary antibody against VWF), used for validation of the 






Figure 3. 2: VWF staining for 10,000 cells per mL primary brain microvascular 
endothelial cells. The left panel represents phase-contrast images, and the right panel 
represents fluorescence images after VWF staining for the same region, VWF stained 
BMVECs (A-B), and negative controls (C-D). Scale bar = 100 um, Magnification 
=200X 
3.3.2 GFAP Staining 
For better visualization and to be able to distinguish and quantify the two different 
BBB cell types used in this research, staining the cells was crucial. The astrocyte cells 
were stained against GFAP, and images were obtained under phase contrast and 
fluorescence microscopy. Figure 3.3 A demonstrates phase contrast images of normal 
brain astrocytes. Only positive controls treated with primary and secondary antibody (1° 
Ab + 2° Ab) (Figure 3.3 B) as mentioned in protocols (Appendix G.4) showed positive 
results for GFAP staining while negative controls not treated with primary antibody (no 
1° Ab) (Figure 3.3 C) showed no staining. From Figure 3.3B, we observed the fine 





Figure 3. 3: GFAP staining for 20,000 cells per mL primary astrocytes. A) Phase 
contrast image before staining B) Fluorescence image of GFAP stained astrocytes C) 
Fluorescence image of negative controls for GFAP staining of astrocytes Scale bar = 
100 µm, Magnification =200X 
To simplify quantification of the area covered by each cell type in the co-culture 
model, astrocyte cells were stained against GFAP (Figure 3.4) and the nuclei of both 
astrocyte and endothelial cells were stained with DAPI for the selected region of interest 
(ROIs) for superior visualization of both cell types in the system. Figure 3.4 shows two 
such ROIs selected for quantification stained with GFAP (green)  and DAPI (Figure 3.4 
A-C) and stained with GFAP (red) and DAPI (Figure 3.4 D-F). 
The GFAP stained pictures of co-culture were then analyzed under image pro 7 
software for analysis of the area covered by astrocytes in the co-culture model. 
3.3.3 Area Analysis  
Figure 3.5 shows the area covered by GFAP staining, which approximated the 
astrocyte area coverage in the co-culture model. The result indicates that astrocytes 
occupied a mean area of 300786±21800 pixel2 in an ROI with a total area of 1383455 
pixel2 as shown in Figure 3.5A, which accounts for 25±1.57 % of area coverage by 
astrocytes in the co-culture model (Figure 3.5B). As the cell growth was terminated 
when the cells reached close to 80% confluency, the approximate area of endothelial cell 





covered by cells per ROI and found to be at 54.4% (Figure 3.5B). Therefore, the co-
culture model consists of approximately twice as many BMVECs as the astrocytes. 
Figure 3. 4: GFAP staining for 20,000 cells per mL co-culture model showing brain 
astrocytes stained against GFAP amongst endothelial cells’ nuclei stained with DAPI.  
Top panel presents images for co-culture model stained against GFAP- Green and 
bottom panel shows images for model stained against GFAP- Red. (A-D) Astrocytes 
in the co-culture model stained against GFAP, (B-E) DAPI image for regions shown 
in (A-D) and (C-F) Merged images for region for (A-B) and (D-E) showing astrocytes 
stained with GFAP amongst the nuclei of endothelial cells. Scale bar = 100 µm. 
Figure 3. 5: A) Mean area coverage by astrocytes per ROI B) Percentage of area 
covered by astrocytes and BMVECs; in the Co-culture model plated with 1:1 ratio 
of Astrocytes and BMVECs for 2 experiments (N=2) with four wells (n=4) each 






3.4 Conclusion and Discussion 
A co-culture model of BMVECs and astrocyte plated at the ratio of 1:1 was developed in 
vitro and characterized through GFAP staining against astrocytes. The area covered by 
astrocytes on the co-culture model was quantified by GFAP image analysis, which was 
used to approximate the area coverage of BMVECs by subtracting the area covered by 
GFAP to the total area of image, considering the cells were ~80 confluent. The results 
showed that the co-culture model consists of nearly two-fold of BMVECs compared to 
astrocytes, which is reasonable, given that astrocytes exhibit slower proliferation than 
endothelial cells (149) and that they require nearly twice as much time to reach the 
confluency, as was observed for BMVECs cultured under same condition in the 
experiments. Different ratios of astrocytes and endothelial cells could be selected for the 
co-culture model to understand the influence of one cell type on other, however it can be 
complicated to control and estimate the cell growth in vitro cultures when uneven ratios 
of cells are selected. 
 The co-culture model was developed to investigate the role of astrocytes in 
influencing the activity of endothelial cells, therefore, a model with lesser number of 
astrocytes compared to endothelial cells provides better validation of influence as it 
prevents the system to be dominated by astrocytes activity. The co-culture system 
developed in this study is simply reproducible and better mimics cell-cell interactions 
than the monocultures.  It is therefore an optimized model to study how the presence of 
astrocyte modulates the BMVECs behavior because it includes cellular interaction 







ASTROCYTES PROVIDE NEGATIVE FEEDBACK TO 
NITRIC OXIDE SYNTHEIS FROM BRAIN 




NO is a vasoactive signaling molecule expressed in both normal and disease states 
in the brain. It generally helps the body to maintain blood pressure at normal levels, but 
this tiny gaseous molecule can be damaging, acting like a prooxidant when recruited by 
the immune system. During neuroinflammation, NO often causes the most damage to key 
glial cells. Activation of microglia, astrocytes, and endothelial cells during inflammation 
results in successive release of cytokines, chemokines, cell adhesion molecules and 
expression of surface antigens which enhance immune cascade in CNS, resulting in 
increased immune cell infiltration into the CNS if left unchecked (150,151). 
Inflammatory reactions are an important contributor to neuronal damage in a wide variety 
of neurodegenerative disorders like PD, AD, and MS, ALS, and some forms of epileptic 
seizures(6). Failure of the BBB has been associated with inflammatory processes and is 
widely being investigated as a key area for drug delivery to treat neuronal and mental 
diseases (152,153). During inflammation, excessive NO synthesis can form the reactive 
nitrogen species, ONOO-, which is a toxic molecule that can cause initiation of the 





promote BBB permeability while its specific role in NO-related tissue injury and BBB 
opening is not yet clear (92).  NO synthesis and modulation in BBB cells during 
inflammation, its effect on cellular networks, and the subsequent changes in Ca++ 
dynamics will provide a better insight to analyze NO-induced neurodegeneration and 
BBB permeability. 
4.2 Materials and Methods 
4.2.1 Cell Culture 
 Primary BMVECs were plated at the density of 10,000 cells (10k) per mL in a 48 
well cell culture plate. The cells were grown in the Rat Endothelial Growth Media (Cell 
Application Inc.) (Appendix C.3), which constitutes rat endothelial growth factor 
(6%v/v) and penicillin/streptomycin (0.5% v/v) and incubated at 5% CO2 and 37 °C until 
they reached ~30% confluency. 
Primary Astrocytes were seeded at densities of 20,000 cells per mL in a 48-well 
cell culture plate, grown in astrocyte media (Appendix C.4) with F-12 Ham media plus 
L-glutamine and sodium bicarbonate (Sigma-Aldrich) with horse serum (5% v/v), fetal 
bovine serum (5% v/v), and penicillin/streptomycin (0.5% v/v), and incubated at 5% CO2 
and 37 °C in a humidified incubator until they reached ~30% confluency. BMVECs 
exhibits a higher proliferation rate than the astrocytes. Therefore, 10k and 20k cell 
densities of BMVECs and astrocytes respectively were selected to maintain confluency 
for both cell types at the approximately same level over time. 
For a co-culture experimental model, BMVECs and astrocytes were seeded at the 
ratio of 1:1 into the same well in their respective growth media with direct cell-cell 





condition as the monocultures until they reach ~30% confluency. Each culture was 
treated with an inflammatory stimulus after they reached ~30% confluency. 
4.2.2 Treatment with Inflammatory Stimulus 
A combination of inflammatory agents, 100 ng/ml of Tumor Necrotic Factor (TNF) 
(Sigma Aldrich), and 5 µg/ml of Lipopolysaccharide (LPS) (Sigma Aldrich) were used to 
treat the cells. The cells were then incubated at 37 °C and 5% CO2 until 6 DIV (days in 
vitro). NO assay was performed to indirectly determine the concentration of NO by 
quantifying the concentration of NO2- , the stable decomposition products of NO. NO2- 
accumulated in each well on 2, 4, and 6 DIV for both cell types and their co-culture 
model was quantified using spectrophotometry.  After each NO assessment, the cells 
were fed with 100 µl of their respective fresh media to compromise for the volume taken 
for the assay. 
4.2.3 NO Assay 
For quantitative colorimetric determination of NO, Invitrogen™ Griess Reagent 
Kit (#LSG-7921) for nitrite quantification was obtained from Thermo Fisher Scientific 
and used according to standard protocols (Appendix I). 100 µL of the sample  
(media from cells treated and non-treated with inflammatory stimulus) was transferred to 
a 1.5 ml Eppendorf tube constituting 866.5 µL of water on top of which 16.5 µL each of 
working reagent A and reagent B were added. Standard curves of 5,25 and 50 µM were 
prepared as well. The mixtures were vortexed to mix the sample and reagent thoroughly 
and incubated in dark at room temperature for 30 minutes. Spectrophotometric 
measurements were carried out using Beckman Coulter DU 800. Absorbance readings for 





to convert the absorbance readings to corresponding NO concentrations values in MS 
Excel.  
4.2.4 Lumen Quantification 
Digital microscopy images of the BMVECs’ cellular networks were taken at 6 
DIV after treatment and before cell fixation for DAPI staining. Three pictures of each 
well were taken by selecting random ROIs for 4 wells (n=4) per condition for 3 different 
experiments (N=3). The empty spaces surrounded by cells (lumens) were quantified for 
their count and area coverage using Image Pro 7 software as shown in Appendix A.2 and 
Figure A.2. 
4.2.5 DAPI Analysis 
The cells were fixed after NO assay on 6 DIV. The nuclei of fixed cells were 
stained with DAPI (4′,6-diamidino-2-phenylindole) (Appendix G.1) to analyze and 
compare the cell proliferation rate and nuclear area factor (NAF) (154) in between the 
cells treated and non-treated with the inflammatory stimulus. DAPI images for both 
treated and non-treated conditions were taken by selecting 3 random ROIs within the 
fluorescence microscopy field. The total count of nuclei and NAF (roundness x size) 
where roundness is defined in the Image Pro 7 as (perimeter2)/ (4 x pi x area) were 
calculated for each ROI and averaged over each condition for 3 different experiments 
using Image Pro 7 software. 
4.2.6 Microscopy 
Microscopic images of the cells were recorded using a Leica DMI 6000B 
microscope. For quantification of the lumen, phase-contrast microscopy was used, while 





Leica EL6000 light source was used with an excitation light in the ultraviolet range (~400 
nm) to view DAPI-stained nuclei. 
4.2.7 Image Analysis 
Image-Pro Plus version 7.0 developed by Media Cybernetics was used to perform 
all image analysis. The total number of lumens and area covered by the lumens in 
BMVECs were determined by analyzing the phase microscopic pictures of selected ROIs 
(Appendix B). For images stained with DAPI, the total number of nuclei and their NAF 
were calculated. 
4.2.8 Statistics 
Statistical analysis was performed as described in Section 3.2.8. 
4.3 Results 
4.3.1 NO Assay  
NO Assay was performed on 2,4 and 6 DIV after treatment with inflammatory 
stimulus for the mono-cultures of BMVECs and astrocytes as well as their co-culture 
model. A non-linear increase in NO synthesis was seen in BMVECs treated with 
inflammatory stimulus compared to the control cells with 3.5±0.5 µM mean increase in 
NO2 concentration on day 2 that increased significantly to 10.5±0.7µM and 26±0.3 µM 
by day 4 and day 6 after treatment, respectively. An opposite trend of NO synthesis was 
seen in astrocytes with NO2 concentration decreasing from day 2 to day 6 after treatment. 
Astrocytes treated with inflammatory stimulus showed a mean increase in NO2 at 
2.5±0.3µM on day 2 compared to the control cells which went down slightly to 2.3±1.4 
µM and 1.2 ± 0.3 µM by day 4 and day 6, respectively. NO synthesis in astrocytes 





decrease, as observed for day 6. The co-culture model shows a salient feature close to 
BMVECs culture with the trend of NO2 concentration in stimulated cells going up from 
day 2 to day 6 after treatment markedly at a reduced level. Mean NO2 increase was seen 
at 1.2±0.1 µM on day 2, 2.2±0.1µM on day 4, and 3±0.3µM on day 6 for the inflamed 
cells compared to the controls.  
 
Figure 4.1: Concentration of NO2 released by BMVECs, astrocytes and their co-
culture model for 2,4 and 6 DIV after preincubation with the inflammatory stimulus 
(100 ng/ml of TNF+ 5ug/ml of LPS) 37 °C. Data represent an average of three 
experiments (N=3) with triplicated wells (n=3), where ‘***’ represents p<0.001 and 
‘**’ represents p<0.01. Error bars represent SEM values.  
BMVECs were also tested for NO synthesis with an individual stimulus of 100 
ng/ml of TNF alone and 5 µg/ml of LPS alone to test the efficiency of the combination of 
the stimulus used for the experiment. No significant production of NO was found in cells 
treated with only one of these stimuli, with the amount of NO2 formed at a level close to 
the control cells. A widely used NO inhibitor, L-NAME (N(ω)-nitro-L-arginine methyl 





release in all conditions thus validating the measured release and inhibition profiles of 
NO in the cells as mediated by NOS enzyme (Appendix A.1). 
4.3.2 Lumen Quantification and Cell Metabolism 
After treatment with the inflammatory stimulus, the BMVECs cells were imaged 
at 3 and 6 DIV to observe morphological changes in the cellular network. The stimulated 
cells showed the formation of lumens (115) in vitro while controls showed no sign or 
minimal sign of lumen formation. Higher metabolism was observed in the stimulated 
cells that showed this change in morphology indicated by a change in pH which is 
represented by the change in color (yellowish) compared to control (reddish) as shown in 
Figure 4.2. 
 
Figure 4. 2: Microscopic images for 10k per mL of BMVECs taken after 
preincubation with the inflammatory stimulus at 37°C at 3 DIV A) Control cells (B) 







The quantification of lumen formation between cellular networks by 6 DIV after 
treatment with inflammatory stimulus showed elevated numbers of lumens in the treated 
wells compared to the controls, which showed only a few or no lumen formation. Image 
pro 7 software was used to quantify the number and area of lumens, as shown in 
Appendix A.2. A mean of 32±1 lumen per ROI was found for the stimulated cells while 
control cells showed a mean of 2±1 lumens per ROI (Figure 4.3A). The total area 
covered by the lumens per ROI was 230,831 ±469 square pixels for the stimulated cells 
and for control it was 15,534±110  square pixels (Figure 4.3B). 
Figure 4. 3: Graphs showing the difference between BMVECs stimulated with 
inflammatory stimulus and controls in A) the number of lumens B) total area covered 
by the lumens - per ROI on 6 DIV. Data represent an average of three experiments 
(N=3) with triplicated wells (n=3), where ‘***’ represents p<0.001. Error bars 
represent SEM values. 
4.3.3 DAPI Analysis 
Cell proliferation and cellular size of BMVECs and astrocyte cells were compared, 
analyzing the total number of nuclei and the nuclear area factor per region of interest 
(ROI) calculated by analyzing the DAPI images as shown in Figure 4.4 of the stimulated 





For BMVECs plated at 5k and 10k per mL, the cells treated with inflammatory 
stimulus showed a nuclei count of 598 ±15 and 594±13, respectively (Figure 4.5), which 
is significantly higher than the control cells.  Control cells showed a nuclei count of 249 
±17 and 330±24. NAF is used to determine the difference between the nuclei size and to 
give us information corresponding to cell size or shrinkage caused by contact inhibition or 
apoptosis. As shown in Figure 4.6, for cells plated at 5k and 10k per mL, stimulated cells 
showed comparatively smaller NAF than control. Control cells plated at 5k and 10k 
densities showed a NAF of 1248±111 and 1101±101 square pixel, respectively, while the 
cells treated with inflammatory stimulus showed an NAF of 825±89 and 796±75 square 
pixel, respectively.  
 
 
Figure 4. 4: DAPI images taken at 6 DIV after preincubation with the inflammatory 
stimulus at 37 °C for 10k per mL of BMVECs (A) Control cells (B) Treated cells and 








Figure 4. 5: Total number of nuclei per ROI controls and stimulated BMVECs plated 
at 5k and 10k per mL after preincubation with inflammatory stimulus for 6 DIV at 37 
°C. Data represent an average of three experiments (N=3) with triplicated samples 
(n=3) each, where ‘**’ represents p<0.01, and ‘*’ represents p < 0.05.  Error bars 
represent SEM values. 
 
Figure 4. 6: NAF per ROI for controls and stimulated BMVECs plated at 5k and 
10k per mL after preincubation with inflammatory stimulus for 6 DIV at 37 °C. 
Data represent an average of three experiments (N=3) with triplicated samples 
(n=3) each, where ‘***’ represents p<0.001 and ‘*’ represents p < 0.05. Error bars 









Figure 4. 7: Total number of nuclei per ROI for controls and stimulated astrocytes 
plated at 10k and 20k per mL after preincubation with inflammatory stimulus for 6 
DIV at 37°C. Data represent an average of three experiments (N=3) with triplicated 
samples (n=3) each, where ‘***’ represents p<0.001 and ‘*’ represents p < 0.05, 
averaged over  3 experiments(N=3) with 3 samples per condition (n=3). Error bars 
represent SEM values. 
 
Figure 4. 8: Nuclear Area Factor per ROI for controls and stimulated astrocytes 
plated at 10k and 20k per mL, after preincubation with inflammatory stimulus for 
6 DIV at 37 °C, where ‘***’ represents p<0.001 and ‘*’ represents p < 0.05, 
averaged over 3 experiments (N=3) with 3 samples per condition(n=3). Error bars 








Figure 4.7 shows that the astrocytes plated at 10k and 20k per mL showed a nuclei 
count of 443±9 and 552±20, respectively, for the stimulated cells.  These counts are 
significantly higher than the control cell counts, which were 164 ±6 and 244±10. NAF was 
found to be 812±16 and 734±6-pixel square control cells which is slightly higher than 
688±13 and 563±9-pixel square of NAF shown by the stimulated cells plated at 10k and 
20k per mL respectively (Figure 4.8). Significantly higher nuclei count and smaller sized 
nuclei in both the BMVECs and astrocyte culture indicate higher cellular proliferation in 
the cells stimulated with inflammatory stimulus. 
4.4 Conclusion and Discussion 
BMVECs monocultures produced significantly high amount of NO over time 
when induced with inflammatory stimulus. The presence of astrocytes in the co-culture 
model significantly inhibited the NO production from BMVECs for the same amount of 
stimulation. This suggests that astrocytes provide negative feedback to the positive 
feedback mechanism of NO synthesis in BMVECs during inflammation, preventing the 
potential neurological pathology due to availability of excess NO in the brain such as the 
toxicity due to ONOO- formation.  
The analysis of morphological changes over time for BMVECs and astrocyte 
culture showed higher cellular proliferation in both cultures when stimulated with 
inflammatory factors, as verified by DAPI image analysis for cell count and NAF. 
BMVEC cultures treated with inflammatory stimulus also showed higher cell 
metabolism, indicated by pH change of media and formation of a significantly larger 
number of irregular lumens or holes in between cellular networks. While the proliferating 





is the indication of vascular morphogenesis, the fully grown culture showed a compact 
cellular monolayer with negligible lumen formation. In contrast, the BMVECs cultures 
induced with inflammation showed changes in cell morphology with increased number of 
lumens formed by stretched out cells networking with each other, which might be due to 
TNF induced shift in cytoskeletal dynamics, as suggested by Stroka et al. (155). The 
increased lumen numbers have often been associated to inflammation induced 
angiogenesis in the literature, however, the lumens persisted even after the cell growth 
was suppressed by contact inhibition in contrast to normal endothelial culture grown in 
media with angiogenic factors. TNF and LPS have also been suggested to degrade 
glycocalyx (156) and disrupt and downregulate TJ protein (157–159), and therefore these 
increased number of irregular lumens between cellular networks, might be an indication 
















COPPER HIGH ASPECT RATIO STRUCTURES CAN 




NO is a bioactive signaling molecule essential for a wide variety of physiological 
conditions such as cardiovascular homeostasis, inflammatory responses, 
immunomodulation, tumor growth, ion channel modulation, and reproduction (160). 
These diverse roles of NO have paved a path for huge research interest in therapeutics 
related to exogenous NO delivery or NO catalysis in vivo for biomedical applications 
(161). In the brain, it has an important role mainly in neuronal signaling and 
neurovascular coupling (NVC)(80,162). The brain microvascular endothelial cells 
(BMVECs) are a major part of the neurovascular unit (163). NO released from these cells 
relaxes the vascular smooth muscle cells and controls blood flow to the brain, thus 
playing a central role in NVC. In this chapter we investigated the role of a copper-cystine 
biohybrid known as Copper High Aspect Ratio Structures (CuHARS) in catalyzing the 
NO production from normal BMVECs, underlining the neuroprotective roles of 
endothelial NO (164–167). As NO donors have been known to modulate oxidative stress 
and inflammation (168), here we attempt to find a therapeutic application of CuHARS for 
brain disorders involving disruption of NVC, oxidative stress, and inflammation such as 





established from the previous chapter that BMVECs produce an excessive amount of 
inducible NO (iNO) during inflammation, in this chapter we also investigated the role of 
CuHARS in altering NO release from BMVECs during inflammation by using the 
inflammatory stimulus, a combination of TNF and LPS. iNO has a possibly neurotoxic 
effect, but also provides flexibility in dealing with immune challenges (169).  An 
understanding of the effect of CuHARS on inflammatory NO may provide for a new 
avenue in mitigating the neurotoxic effect of iNO during inflammation, besides indicating 
new wound-healing strategies in other regions of the human body pertaining to 
antimicrobial, antithrombotic, and anti-inflammatory properties of NO (170,171).  
5.2 Materials and Methods 
 Chemicals 
CuHARS are novel materials that are completely biodegradable and 
biocompatible metal-organic biohybrids (MOBs). The CuHARS were discovered and 
synthesized in our lab (Cellular Neuroscience Lab) by self-assembly technique and 
primarily consists of metallic copper conjugated with L-Cystine. S-nitrosocysteine 
(CysNO), a NO precursor normally found in blood freshly prepared at a concentration of 
0.1 mM, before each experiment as described by Harding and Reynolds (168). A 0.1mM 
solution of Cystine was mixed with 0.1 mMol of tertbutylnitrite in 2 ml of water set up in 
an ice bath in a stirrer for 30 mins.  
 Cell Culture 
BMVECs cells were plated at the density of 10k per well in 48 well cell culture 
plates and incubated at 5% CO2 and 37 °C. When the confluency of cells reached ~ 60% 





treated with 10 and 20 µg/ml of CuHARS in the presence of three different concentration 
of CysNO, 10, 25, and 50 µM. The cells were incubated for 4 hours with CuHARS and 
CysNO.  CRL2303 cell lines were obtained from American Type Culture Collection 
(ATCC) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) constituting 
fetal bovine serum (5% v/v), amino acid solution (1%v/v), and penicillin/streptomycin 
(0.5% v/v), (Appendix C.5) CRL 2303 cells line were used as negative controls to 
validate NO catalysis in BMVECs.  
5.2.3 CuHARS Treatment in Combination with CysNO 
Endothelial cells were plated in 48 well cell culture plates at the density of 10,000 
per ml. When the confluency of cells reached ~60%, the cells were treated with 0.1mM of 
S-nitrosocysteine (CysNO). Three concentrations of CysNO, 10, 25, and 50 µM, were 
chosen to obtain NO release profile using 10 or 20 µg/ml of CuHARS. CuHARS were 
added immediately after CysNO to the cells which were then incubated at 37 C and 5% 
CO2 for 3 hours. The experiment was replicated with glioma cells for 25 and 50 µM of 
CysNO treatment. 
5.2.4 CuHARS Treatment in Combination with an Inflammatory Stimulus 
The BMVECs plated at 10,000 per ml in 48 well cell culture plates were treated 
with an inflammatory stimulus, a combination of 100 ng/ml of TNF and 5 µg/ml of LPS in 
the presence and absence of 20 µg/ml of CuHARS when the cells reached ~30% 
confluency. The cells were incubated at 37 C and 5% CO2 for up to 96 hours after 
treatment to assess the NO release in the cells caused by the inflammatory stimulus. The 





experiment was replicated in glioma cells to compare NO release at 48 hours after 
treatment. 
5.2.5 NO Assay 
For quantitative colorimetric determination of NO, Invitrogen™ Griess Reagent Kit 
(#LSG-7921) for nitrite quantification was obtained from Thermo Fisher Scientific and 
used according to standard protocols (Appendix I). A sample of media (100µl) is 
collected from the wells after incubation with their respective treatment conditions. The 
samples were reacted with Griess Reagent for nitrite (NO2), a stable breakdown product 
of NO) determination as described in the protocol (Invitrogen, G-7921) (Ashpole et al., 
2014). The absorbance values of the solution obtained were read using a 
spectrophotometer (Beckman Coulter DU 800) at 548 nm. For each experiment, a 
standard curve with four to five standard solutions of nitrite (0, 5, 25, 50, and 75 µM) 
obtained from the reagent kit was prepared, which was used to convert the absorbance 
values into NO2, concentrations.  
5.2.6 MTT Assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a 
biochemical assay used to determine the metabolic rate of cells. MTT was obtained from 
Thermo Fisher Scientific (Waltham, MA). MTT assay was used as the measure of 
cytotoxicity by comparing cellular metabolic activity caused by the presence of CuHARS 
and CysNO. It was performed as described by Vives et al. (102). To determine the 
cytotoxicity of the treatment, MTT assay was carried out in the presence and absence of 10 
and 20 µg/mL of CuHARS in cells treated with 0, 10, 25, and 50 µM of CysNO. A 





red was added to each well after aspirating the media from the cells. The plate was 
incubated in a dark environment at 5% CO2 and 37 C for 60 minutes. After incubation, 
purple colored formazan crystals formed on the wells were dissolved with 250 µL of 91% 
isopropyl alcohol. The resulting solution was transferred into 96 well plate and absorbance 
was read at 570 nm, using a 96-well microplate plate reader (Thermo Scientific Multiskan 
Spectrum). For CuHARS and CysNO treatment to cells, MTT assay was performed after 
24 hours of treatment while for the cells treated with CuHARS and inflammatory stimulus, 
it was performed soon after NO assessment at 96 hours for BMVECs and 48 hours for 
glioma cells.  The cell metabolic activity was analyzed by comparing the absorbance values 
of the experimental wells treated with different concentrations of CuHARS and CysNO or 
inflammatory stimulus with the absorbance of control wells. 
Figure 5.1 represents a schematic that explains the overall experimental layout. 
 







 CuHARS Treatment in Combination with CysNO 
5.3.1.1 NO Assay 
BMVECs with no treatment and those treated with CuHARS alone (controls), 
showed no significant increase in NO concentration, while treatment with different 
concentration of CysNO (10, 25 and 50 µM) at two concentrations of CuHARS (10 and 
20 µg/mL) yielded a concentration-dependent increase in NO release from the BMVECs. 
The lower concentration (10 µg/mL) of CuHARS treatment on BMVECs yielded a mean 
increase of 1.16±0.41, 4.40±0.15, and 5.62±1.09 µM of NO2 in presence of 10, 25 and 50 
µM of CysNO, respectively (Figure 5.1). This increase in NO2 concentration was greater 
with the use of a higher concentration (20 µg/mL) of CuHARS for the same 
concentrations of CysNO used. The mean increase in NO2 was found to be 3±0.25, 4.42± 
1.21, and 13.98 ± 4.13 µM in presence of 10, 25 and 50 µM of CysNO, respectively 
(Figure 5.2). For the conditions with no cells (media only), the NO2  yield was closer to 
the cells treated with CysNO alone and less by 2.3±0.27, 6.2±1.48, and 14.6 ±4.15 µM 







Figure 5.1: NO2  concentration in the presence and absence of 10 µg/mL of CuHARS 
for treatment of 0,10,25 and 50 µM of CysNO in BMVECs plated at 10k per mL, 
after 3 hours of incubation at 37 °C, where ‘***’ p<0.001 and ‘*’ represents p < 0.05, 
averaged over  5 experiments (N=5) with 3 samples per condition (n=3). Error bars 
represent SEM values. 
 
Figure 5. 2:  NO2 concentration in the presence and absence of 20µg/mL of 
CuHARS for treatment of 0, 10, 25 and 50 µM of CysNO in wells with cells 
(BMVECs) plated at 10k per mL and wells without any cells (media only), after 3 
hours of incubation at 37 °C, where ‘***’ p<0.001, ‘**’ represent p<0.01 and‘*’ 
represents p < 0.05, averaged over  3 experiments (N=3) with 3 samples per 







 Replication of the same experiment in CRL2303 with CuHARS (20 µg/mL) and 
CysNO (25 and 50µM) resulted in a slight increase of NO2  yield of 1.58±0.57 µM and 
2.56±0.5 µM, respectively, which is significantly less than the yield observed in 
BMVECs (Figure 5.3). No synthesis of NO2  was seen in the CRL2303 cells in the 
controls. 
 
Figure 5. 3: NO2 concentration in the presence and absence of 20 µg/mL of CuHARS 
for treatment of 0, 25 and 50 µM of CysNO in wells with CRL2303 cell line plated at 
10k per mL after 3 hours of incubation at 37 °C, where ‘***’ represent p<0.001, 
averaged over  3 experiments (N=3) with 3 samples per condition (n=3). Error bar 
represents SEM values. 
 
5.3.1.2 MTT Assay 
MTT assay of CuHARS treatment on BMVECs in the presence of CysNO showed no 
toxicity to the cells but indicated higher cell metabolism between 10 to 20% by 24 hours 





increased by a mean of 2 to 17% for different concentrations of CysNO used (Figure 
5.4). The cell metabolism increased by a mean of 10% for the control cells and by 25% at 
10 µM, 15% at 25 µM, and 3% at 50 µM CysNO for cells treated with 20 µg/mL of  
CuHARS compared to the cells treated with CysNO alone (Figure 5.6). The toxicity of 
CuHARS on the BMVECs cells without any treatment was also assessed using the Diff 
Quik staining technique for 24 hours treatment on the cells and compared with CuNPs 
that act as positive controls for toxicity in cells. CuHARS were found to be significantly 
less toxic compared to CuNPs at the same concentration of 6 µg/ml (Figure A.3 -A.4, 
Appendix A). 
 
Figure 5. 4: Cell metabolism as a measure of cell viability for 10k BMVECs after 
incubation with 0, 10, 25 and 50 µM of CysNO in the presence and absence of 10 
µg/mL of CuHARS, after 24 hours of incubation at 37 °C, where ‘***’ p<0.001 and 
‘*’ represents p < 0.05, averaged over  3 experiments (N=3) with 3 samples per 






Figure 5. 5: BMVECs plated at 10k per mL (A) Controls (B) Cells treated with 10 
µg/mL of CuHARS at 24 hours after treatment showing no toxicity to the cells, 
Magnification 200X, Scale=100 µm. 
 
Figure 5. 6: Viability of 10k BMVECs after incubation with 0, 10, 25 and 50 
µM of CysNO in the presence and absence of 20 µg/mL of CuHARS, after 24 
hours of incubation at 37 °C, where ‘***’ represents p<0.001 and ‘*’ 
represents p < 0.05, averaged over  3 experiments (N=3) with 3 samples per 
condition (n=3). Error bar represents SEM values. 
  
MTT assay at 24 hours after treatment in glioma cells for the same treatment 





CuHARS alone (20 µg/ml) compared to non-treated cells. The cells treated with 25 and 
50 µM CysNO alone showed a slight increase in cell metabolism at lower concentrations 
(25 µM) which decreased slightly with higher concentrations used. This increase in cell 
metabolism by CysNO was reversed by the presence of 20 µg/ml CuHARS which 
inhibited the metabolism by 13 and 7% for cells treated with 25 and 50 µM CysNO, 
respectively (Figure 5.7). As CuHARS is a slowly degrading material, the viability for 
glioma cells continues to decrease with increasing time in response to the toxicity 
imparted by the release of copper from CuHARS, as shown in Karekar et al. (169) and 
further demonstrated by the following sections of this research.  
 
Figure 5. 7: Cell metabolism as a measure of cell viability for 10k glioma cells 
(CRL2303) after incubation with 25 and 50 µM of CysNO in the presence and 
absence of 20 µg/mL of CuHARS after 24 hours of incubation at 37 °C, where ‘***’ 
p<0.001, ‘**’  represents p < 0.01 and ‘*’ represents p < 0.05, averaged over  3 







 CuHARS Treatment in Combination with an Inflammatory Stimulus 
5.3.2.1 NO Assay 
NO concentration was measured on the BMVECs with the inflammatory stimuli 
(100 ng/ml TNF+5 µg/ml LPS) in the presence and absence of 20 µg/ml of CuHARS. 
The concentration of NO increased significantly for BMVECs supplied with 
inflammatory agents compared to the controls, but strikingly, the presence of CuHARS 
inhibited the NO release from these stimulated cells in contrast to the results observed for 
normal cells when the NO donor, CysNO is supplied as discussed in Section 5.3.1. NO2  
absorbance readings were taken at 48 hours and 96 hours. At 48 hours, an increase in 
4.9±0.5 µM of NO2  was observed in BMVECs stimulated by inflammatory agents alone 
compared to the control cells which were inhibited by 1.8±0.6 µM due to the presence of 
20 µg/ml CuHARS and by 96 hours these values went up to 9.6±0.5µM increase and 
3.1±0.7µM inhibition respectively (Figure 7A). Treatment of wells with L-NAME 
resulted in significant inhibition of NO release in all conditions thus validating the 






Figure 5. 8: NO2 concentration in the BMVECs due to the treatment of inflammatory 
stimulus in the presence and absence of 20µg/ml of CuHARS and negative controls 
treated with LNAME, a NOS inhibitor. Data represent an average of three 
experiments(N=3) with triplicated wells (n=3). The error bars represent SEM 
values,“***” represents p<0.001, “**” represents p<0.01, and “*” represents p<0.05.  
In contrast to results observed for BMVECs, a two-fold increase in NO2 synthesis 
(2.2 µM) was observed in glioma cells treated with the inflammatory stimulus in the 
presence of 20 µg/ml of CuHARS compared to the cells treated with the inflammatory 
stimulus alone (1.1 µM), 48 hours after the treatment (Figure 5.9).  Treatment with 
inflammatory stimulus resulted in a modest increase of 0.5±0.2 µM of NO2 while the 
combinatory treatment of the stimulus and CuHARS led to an increase of 1.6±0.2 µM 
compared to the non-treated control cells. The addition of (N(ω)-nitro-L-arginine methyl 
ester (LNAME), a NOS inhibitor to the system, resulted in significant inhibition of the 
NO produced in the wells, thus validating the conclusion that NO increase was caused by 






Figure 5. 9: NO2 concentration in the BMVECs due to the treatment of inflammatory 
stimulus in the presence and absence of 20µg/ml of CuHARS and negative controls 
treated with LNAME, a NOS inhibitor. Data represent an average of three 
experiments(N=3) with triplicated wells (n=3). The error bars represent SEM 
values,“***” represents p<0.001, and “*” represents p<0.05. 
5.3.2.2 MTT Assay 
MTT results for BMVECs treated with inflammatory stimulus showed a more 
than 2 fold increase in cell metabolism compared to the controls at 96 hours time point. 
The cells treated with the combination of inflammatory stimulus and CuHARS showed 
slight inhibition in metabolism compared to those treated with inflammatory stimulus 
alone, but a  significant increase in metabolism compared to the controls with no 
treatment and treated with CuHARS alone. No significant inhibition was observed in the 
presence of CuHARs on normal BMVECs and the metabolism was reduced by 12% for 
stimulated cells and 14% for the LNAME treated cells showing the inhibitory potential of 







Figure 5. 10: Graph showing cell viability in 10K BMVECs after the treatment, 
indicating a significant increase in cell metabolism in BMVECs treated with 
inflammatory stimulus alone, compared to the controls and slight inhibition due to 
CuHARS in the cells treated with the combination of CuHARS and inflammatory 
stimulus. Data represent an average of three experiments(N=3) with triplicated wells 
(n=3). The error bars represent SEM values,“***” represents p<0.001, “**” represents 
p<0.01, and “*” represents p<0.05. 
Morphological evaluation of cells treated with the inflammatory stimulus or with 
inflammatory stimulus plus CuHARS in glioma cells supported metabolic biochemical 
assays (Figure 5.11 and Figure 5.12).  CuHARS could be observed under inverted phase 
microscopy in cultures treated with 20 µg/ml of the materials (Figure 5.11C), and when 
combined with inflammatory stimulus, this diminished cell number compared to control 





Figure 5. 11: Glioma cells treated with the inflammatory stimulus in presence of 
20µg/ml of CuHARS causes significant toxicity to the cells. A) Control cells treated 
with media alone B) Cells treated with inflammatory agents C)  Cells treated with 
inflammatory agents and 20µg/ml of CuHARS, Scale bar=100µm; 
Magnification=200X. 
 An MTT assay was performed after 48 hours of treatment to quantify cellular 
metabolism of glioma cells with no treatment (controls) and with the treatment of 
inflammatory stimulus in the presence or absence of 20 µg/ml of CuHARS to determine 
the cytotoxicity of the treatment. The assay indicated no significant difference in cell 
metabolism for glioma cells treated with inflammatory agents computed by comparison 
to the control conditions. In contrast, the metabolism of cells treated with CuHARS 
decreased in all conditions treated with CuHARS with a significant decrease of 25% by 
48 hours in line with the 10% decrease observed within 24 hours for controls (Figure 
5.7). The cytotoxicity of the treatment was explicitly visible under the microscope as 
shown by images captured from the Leica DMI 6000B microscope (Figure 5.11). For the 
cells treated with inflammatory agents in the presence of CuHARS, metabolism 
decreased by 15% only, which can be compared to increased metabolic activity after 
treatment with inflammatory agents in other cell types (170,171).  Suppression of NO 
release on cells treated with L-NAME led to decreased cell metabolism by 10%, which 







Figure 5. 12: Cell viability as measured by the MTT assay.  No increase in cell 
viability was seen in glioma cells treated with inflammatory stimulus alone, compared 
to the controls, and significant inhibition was seen after treatment with CuHARS in 
the control cells and in cells treated with the combination of CuHARS and 
inflammatory stimulus. Data represent an average of three experiments(N=3) with 
triplicated wells (n=3). The error bars represent SEM values,“***” represents 
p<0.001, and “*” represents p<0.05. 
5.4 Conclusions 
CuHARS can catalyze NO production in BMVECS when interacted with CysNO, 
an NO precursor normally found in the blood thus significantly increasing NO 
availability in blood and posing a therapeutic potential for brain conditions related to NO 
and NVC disorder. The NO concentration thus formed depends on the availability of both 
CuHARS and CysNO, as shown by the increase in NO release with increasing 
concentration of CysNO and CuHARS used. The reaction is limited only by the 





hours) while CuHARS are known to last longer (days) depending on the cell types. The 
significant inhibition of NO with the use of LNAME validates the NO increase after 
CuHARS treatment, as measured via the enzyme NOS. The glioma cell line (CRL2303) 
is used as a negative control for NO synthesis, and the positive control for cytotoxicity 
shows significantly less NO release and an explicit toxic response compared to 
BMVECs, thus further supporting the role of CuHARS as a NO catalyst in BMVECs,  
This role is potentially neuroprotective and may be useful for treatment of abnormalities 
of NVC disorders.  CuHARS's role in inhibiting inducible NO (iNO) during 
inflammation, which has neurotoxic roles, further reinforces its potential neuroprotective 
property. The ability to target and inhibit glioma cell lines without affecting the cellular 
metabolism of the structural cell BMVECs while increasing the production of NO, a key 
contributor of an immune response in glioma (165,172), stretches the scope of CuHARS 









ASTROCYTES MODULATE THE CALCIUM 




Calcium is the second messenger of diversified signaling pathways such as energy 
production, synaptogenesis, synaptic transmission, neuronal gene expression, cell 
survival, and processes central to learning and memory.  It therefore plays a fundamental 
role in neuronal plasticity (118). Endothelial cells control the vascular tone in a Ca++ 
dependent manner, but most of the research related to NVC has been biased towards the 
role of neurons and astrocytes in triggering NVC (119). Intracellular calcium 
concentration ([Ca++] i) is a key controller of BBB permeability with an increase in Ca++ 
interfering with tight junction development (120). Ca++ overloading and excessive NO 
production along with other events like radical formation have been an area of interest as 
they contribute altogether to a wide variety of brain damage (113).  
In Chapter 4, an excessive increase in NO was found over time in BMVECs 
during inflammation, where astrocyte can provide negative feedback to this NO, thus 
inhibiting the NO production from BMVECs in the coculture model. Our specific 
objective in this chapter is to test the role of NO in calcium activity of the BMVECs and 
astrocytes.  A widely used NO donor sodium nitrite (NaNO2)(173–175) will be applied, 





(176).  Results are expected to show that endothelial NMDA has a role in NO-dependent 
calcium activity, as suggested earlier by Lemaitre et al. (177). Further, we will analyze 
the effect in calcium activity after inflammatory stimulation, which represents a cascade 
of chemical signaling,  not merely the alteration of NO, in the BMVECs and astrocyte 
cultures.  We will test how the cellular interaction between the two cell types alters the 
Ca++ activity in the co-culture model during inflammation.  
6.2 Materials and Methods 
6.2.1 Chemicals 
Calcium indicator dye, Fluo-3 AM was obtained from Invitrogen. Locke’s 
solution was prepared in the lab following Locke’s protocol (Appendix C.6). Agonists 
adenosine triphosphate (ATP), glutamic acid (Glu), and d-serine were bought in powder 
form (Sigma). Ionomycin (Iono) is the calcium ionophore that facilitates the movement 
of calcium in and out of the cells, is used as a positive control for calcium influx in the 
cells.  
6.2.2 Cell Culture 
 Primary BMVECs and astrocytes were seeded at the density of 10,000 (10k) and 
20000 (20k) per mL respectively, as mentioned Section 4.2.1. The cells were grown until 
they reached ~70% confluency for experiments designed to study the effect of NO donor 
in calcium activity of cells, while the cells for experiments designed to study 
inflammation-related calcium changes were treated with inflammatory stimulus when 
they reach ~30% confluency. The co-culture model was also grown at the same condition 





6.2.3 Calcium Activity in BMVECs and Astrocytes with NO Donors 
Since an excessive increase in NO over-time was found in response to 
inflammatory stimulus in BMVECs, our objective here is to see how NO affects the 
calcium activity in BMVECs and astrocyte cells. BMVECs were treated with an NO 
donor, sodium nitrite (NaNO2) in the presence and absence of d-serine, an  NMDA co-
agonist which has been suggested to help in vasodilation in the eNOS-dependent 
mechanism when used in combination with glutamate (173). 
6.2.3.1 Calcium Imaging after Treatment with NO Donor 
 Calcium imaging was performed on BMVECs and astrocytes after they reached 
the confluency ~75%.  First, the cells were loaded with 500 µl of Fluo-3 loading solution. 
The loading solution constitutes warm Locke’s solution with Fluo-3 dye (1:500) and 
Pluronic acid (1:1000). The cells were treated with this solution for 1 hour at 37 °C, in a 
5% CO2 incubator. After an hour of incubation, the loading solution on the cells was 
pipetted out and the cells were treated with 500 µl of recovery solution which constitutes 
Locke’s solution warmed at 37 0C. The cells were incubated in the recording solution for 
45 mins at 37 0C, in 5% CO2. During the loading and the recovery phase, the 
experimental wells were treated with 5 µM of (NaNO2) in the presence and absence of 
100 µM of D-serine (DS), both diluted in Locke’s solution, making a total incubation 
time of 1 hr and 45 mins. The control wells were treated with Locke’s alone. The cells 
were imaged after the recovery period while being stimulated with three different 
agonists, ATP 100 µM, Glutamate 100 µM, and Ionomycin 1 µM to induce calcium 
signaling. Fluorescent intensity changes in the cells in real-time, which corresponds to the 





under the inverted microscope (Olympus CKX41) with a 488 nm excitation wavelength 
filter at a frame rate of 4 seconds. The experiment was visualized and recorded in the 
Intracellular Imaging software (InCyt Im™ Imaging system, version 5.29e, Cincinnati, 
OH). Figure 6.1 presents the schematics for recording calcium signals from BMVECs 




Figure 6. 1: Experimental layout for calcium imaging in BMVECs and astrocyte cells 
for treatment with NO donors in the presence and absence of D-serine. 
6.2.3.2 Measuring and Analyzing Calcium Fluorescence Intensity  
The recorded experiments were analyzed in InCyt Im™ Imaging System software. 
Regions of interest (ROIs) were created as a circle around each cell constituted in a 
frame. ROIs were selected in the frame with maximum fluorescence in response to ATP 
stimulation to maximize the visualization and analysis of the number of cells in the 
frame. The ROIs were then used to measure the fluorescence intensity of each cell over 
time. The data obtained for fluorescence intensity over time for each ROI were then 
normalized to their starting values (baseline) in Microsoft Excel, for obtaining correlation 
between cells within an experiment and with other experiments. The normalized values 





fluorescence intensity, number of oscillations, decay time,  and number of cells 
responding or not responding to a stimulus, were calculated depending on the experiment, 
and the values were averaged over 3 experiments. 
6.2.4 Calcium Activity in BMVECs, Astrocytes and Co-culture Model using 
Inflammatory Stimulus 
After finding out the response of NO donors in the BMVECs and astrocytes, a 
calcium activity study was performed on BMVECs, astrocytes, and co-culture models 
using inflammatory stimulus. 
6.2.4.1 Treatment with Inflammatory Stimulus 
A combination of inflammatory agents, 100 ng/ml of Tumor Necrotic Factor (TNF) 
(Sigma Aldrich), and 5 µg/ml of Lipopolysaccharide (LPS) (Sigma Aldrich) were used to 
treat the cells when they reach ~30% confluency. The cells were incubated at 37 °C and 
5% CO2 until 4 DIV after treatment.  
6.2.4.2 Calcium Imaging 
Calcium imaging was performed on the 4th day after the treatment with 
inflammatory stimulus. As shown in Figure 6.2, first, the cells were loaded with 500 µl 
of Fluo-3 loading solution. The loading solution constitutes warm Locke’s solution with 
Fluo -3 dye (1:500) and Pluronic acid (1:1000). The cells were treated with this solution 
for 1 hour at 37 °C, in a 5% CO2 incubator. After an hour of incubation, the loading 
solution on the cells was pipetted out and the cells were treated with 500 µl of recovery 
solution which constitutes Locke’s solution warmed at 37 ºC. The cells were incubated in 
the recording solution for 45 mins at 37 º C, in 5% CO2. The recovered cells were 





Ionomycin 1 µM to induce calcium signaling. Fluorescent intensity changes in the cells 
in real-time corresponding to the calcium influx due to stimulation via agonist were 
imaged and recorded in real-time under the inverted microscope (Olympus CKX41) with 
a 488 nm excitation wavelength filter at a frame rate of 4 seconds. The experiment was 
visualized and recorded in the Intracellular Imaging software. 
 
Figure 6. 2: Experimental layout for calcium imaging in BMVECs, Astrocytes, and in 
their co-culture model after treatment with the inflammatory stimulus, a combination 
of TNF and LPS. 
6.2.4.3 Measuring and Analyzing Calcium Fluorescence Intensity  
 Calcium fluorescence intensity was measured and analyzed as mentioned 
above in Section 6.2.3.2. 
6.3 Results 
 Calcium Activity in BMVECs and Astrocytes After Treatment with NO 
Donor 
The Ca++ peak response was upregulated in the BMVECs pre-treated with D-





and (b)) for stimulation of 100 µM ATP. For cells treated with sodium nitrite alone, the 
peak calcium was conspicuously higher and came down quicker than the controls (Figure 
6.3 (c)) while the Ca++ peaks for the cells treated with sodium nitrite in presence of D-
serine resulted in a significant number of calcium oscillations clearly distinguishable by 
visual observations (Figure 6.3d). 
 
Figure 6. 3: Calcium signals recorded for BMVECs when stimulated with agonists 
ATP 100 µM, Glutamate (Glu) 100 µM and Ionomycin (Iono) 1 µM in A) Controls 
B) Cells treated with D-serine alone, C) Cells treated with sodium nitrite alone, and 
D) Cells treated with a combination of D-serine and sodium nitrite. The X-axis 
represents time and Y-axis represents normalized fluorescent intensity values. 
 The reproduction of the same experiment with astrocytes showed that astrocyte 
culture was more responsive to glutamate (100 µM) stimulation after ATP compared to 





response to both sodium nitrite treatment alone, and in presence of D-serine was 
significantly reduced compared to the results found in BMVECs with no conspicuous 
difference found for the treatment conditions when compared to controls. 
 
Figure 6. 4: Calcium signals recorded for astrocytes when stimulated with agonists 
ATP 100 µM, Glutamate(Glu) 100 µM and Ionomycin (Iono) 1 µM in A) Controls, 
B) Cells treated with D-serine alone, C) Cells treated with sodium nitrite alone, and 
D) Cells treated with a combination of D-serine and sodium nitrite. The X-axis 
represents time and,  Y-axis represents normalized fluorescent intensity values. 
Table 1: Database showing a total number of cells, frames, and data points analyzed for 
BMVECs  and astrocytes to study  the effect of NO donor in calcium activity of the cells. 
   Data Frame Total cell 
BMVECs Culture 123,138 1766 1396 






As observed in Figure 6.3 significant changes in calcium signals were recorded in 
BMVEC cultures for the different treatment condition considered and therefore the 
calcium signals were further analyzed for quantifying the peak fluorescence intensity that 
corresponds to peak calcium influx in the cell, the number of oscillating cells, time taken 
per oscillation, and the time taken for the signal to decay to baseline, for all the treatment 
conditions in the experiment. However, astrocytes did not show notable calcium changes 
for the treatment (Figure 6.4) as was observed for BMVECs and hence the data were not 
analyzed for obtaining further information as in the case of BMVECs.  
In BMVEC cultures, the results were analyzed for all the cells that showed 
calcium response above the normalized threshold fluorescence values i.e. 1.2 or 20% 
above baseline for ATP stimulations. Peak Ca++ response of BMVECs cells with ATP 
stimulation was 21.3%, 42.7%, 54.3%, and 346% above baseline for BMVECs controls, 
treated with D-serine alone, nitrite alone, and the combination of nitrite and D-serine, 
respectively, with corresponding mean peak fluorescence intensity values of 1.21,1.42, 
1.54, and 4.4 (Figure 6.5a). Hence, cells treated with NO donor sodium nitrite in 
presence of D-serine showed significantly increased peak calcium response compared to 
all other conditions, while the cells treated with D-serine alone showed around 2-fold 
increase and cells treated with nitrite alone showed a 2.5-fold increase in peak calcium 






Figure 6. 5:  Graph showing results for calcium signal analysis for BMVECs cells 
controls, treated with D-Serine (DS), Sodium Nitrite (NO2 ), and a combination of DS 
and NO2.  A) Normalized Peak fluorescence intensity B) Time is taken per oscillation 
for each treatment condition, C) Percentage of cells above the threshold for 
fluorescence intensity(1.2)  Vs percentage of oscillating cells and D) time taken for 
the signal to decay. The data represents an average of 3 experiments (N=3) with n= 27 
to 114 number of samples (cells) in an experiment. The error bar represents SEM 
values and ‘*’ represent p<0.5. 
The time taken for each oscillation/flickering with a peak above or on the baseline 
for ATP stimulation was analyzed for each condition of treatment and was found to be at  
 28.6, 20.3, 18.29, and 14.27 s per oscillation for BMVECs controls, treated with D-
serine alone, nitrite alone and the combination of nitrite and D-serine respectively 





exhibited more oscillations and higher frequency compared to all other conditions, as the 
frequency is inversely proportional to period (f=1/T).  
For BMVECs controls, treated with D-serine alone, nitrite alone, and the 
combination of nitrite and D-serine, the percentage of cells above the threshold were 
found to be at a mean of 37.5%, 31.8%, 28.4%, and 42.5%, respectively per ROI, while 
the percentage of oscillating or flickering cells were found to be 29.5%, 26.5%, 14.5% 
and 38.5%, respectively (Figure 6.5c). The result suggests that the cells treated with NO 
donor, sodium nitrite in presence of D-serine have a higher number of cells oscillating as 
well as responding to the ATP stimulation compared to all other conditions while 
strikingly, cells treated with sodium nitrite alone had the least number of cells responding 
and oscillating to the stimulation. 
The calcium signals recorded were also analyzed for the time taken for the 
calcium response to come to the baseline after the occurrence of the peak, termed as the 
decay of the signal. The times taken for the Ca++ signal to decay were found to be 58.6, 
53.3,53.3, and 162.6 s for BMVECs controls, treated with D-serine alone, nitrite alone, 
and the combination of nitrite and D-serine, respectively (Figure 6.5d), thus suggesting 
that the Ca++ signals recorded for BMVECs treated with nitrite in presence of d-serine 
stayed for considerably higher time and cells were active for longer time point for the 
same ATP stimulation compared to all other conditions where the signal decayed to 
baseline by nearly same time point. 





Table 2: Database showing a total number of cells, frames, and data points analyzed per 
treatment condition to study the effect of NO in calcium activity in the endothelial cells 
per the condition of treatment. 
 
Data Point Frame Total cell 
Control 21,301 338 251 
DS treated 19,944 301 249 
NO2 treated 30,385 350 342 
DS+NO2 treated 34,249 395 339 
 
6.3.2 Calcium Activity in BMVECs, Astrocytes, and Co-culture Model Treated 
with Inflammatory Stimulus. 
Figures 6.6 and 6.7 show images of cells recorded during calcium imaging for 
BMVECs cells and co-culture model, respectively.  Figure 6.6 shows the images of cells 
representing peak calcium response for ATP stimulation for normal cells and cells 
induced with inflammation. The cells treated with inflammatory stimuli showed the 
characteristic morphological changes (lumens in between cellular networks) observed in 
Chapter 4 and significantly higher fluorescence intensity compared to the control cells. 
Figure 6.8 shows the periodic images for co-culture model controls, before and after 









Figure 6. 6: Images showing the difference in cell morphology and fluorescence 
intensity at peak calcium response to ATP stimulation for  BMVECs -  A) control and 
B) treated with inflammatory stimulus. 
 
Figure 6. 7: Peak Fluorescence intensity in Co-culture model A) before 
stimulation B) after ATP stimulation and C) after ionomycin  stimulation, showing 
networking between BMVECs and astrocytes in the culture, clearly visible during 
calcium imaging. 
 
The Ca++ peaks recorded for BMVECs cells shows that the cells stimulated with 
the inflammatory stimulus (TNF+LPS), which showed excessive NO release in Section 
4.3.1 exhibited significantly higher calcium influx with notable Ca++ oscillations 






Figure 6. 8: Calcium dynamics in [1] BMVECs –A) Controls B) Stimulated ; [2] 
Astrocytes– C) Controls D) Stimulated; [3] Co-Culture - E) Controls  F)  Stimulated, 
in response to agonists ATP, Glutamate and Ionomycin. The X-axis represents time , 
Y-axis represents normalized fluorescent intensity values 
The astrocytes were less responsive to the ATP stimulation than the BMVECs 
control cells (Figures 6.8a and 6.8c). In line with the results observed for BMVECs, 
astrocytes also showed a slight increase in Ca++ in the cells treated with inflammatory 
stimulus compared to astrocyte controls in response to ATP stimulation (Figures 6.8c 





Ca++ increase in BMVECs was nearly threefold higher for BMVECs cells when 
compared to the astrocytes as shown in Figures 6.8b and 6.8d. Astrocytes seem to be 
more responsive to stimulation of glutamate 100 µM (after ATP 100 µM) compared to 
BMVECs Figures 6.8and 6.8c, while the difference in glutamate stimulations for both 
controls and stimulated cells was not significant enough as was observed for ATP. In the 
co-culture model, the Ca++ influx for the same stimulation of ATP (100 µM) showed 
significantly inhibited calcium response compared to BMVECs treated with the 
inflammatory stimulus (Figures 6.8b and 6.8f). The average Ca++ influx was seen 
slightly higher or at a similar level as was observed for astrocytes. 
Peak calcium response, the total number of cells per ROI, and the percentage of 
cells responding to the ATP stimulation were further analyzed for BMVECs, astrocytes, 
and the co-culture model.  
6.3.2.1 Peak calcium response 
Figure 6.9 presents the analysis of peak calcium response that corresponds to the 
normalized fluorescence intensity values above baseline (before stimulation), showed a 
10-fold increase in BMVECs cells stimulated with inflammatory cells compared to the 
BMVECs control cells with 139% and 13% increase respectively in mean peak Ca++ 
response from baseline. In the case of astrocytes, the peak calcium response for cells 
stimulated with the inflammatory stimulus was around 3-fold higher than for the control 
cells with a 14% and 4% increase in mean peak calcium response, respectively, above the 
baseline. When compared to the BMVECs the mean peak calcium influx for stimulated 





BMVECs, while the astrocytes control response was reduced by approximately 3-fold 
compared to BMVECs control cells. 
 
Figure 6. 9: Peak calcium response analysis in Control cells  (Blue) and cells 
stimulated with the inflammatory stimulus (Red) for BMVECs, astrocytes, and their 
Co-culture model, in response to ATP stimulation. Data represent the averages of  
N=3 experiments with two wells per condition, and no. of samples (cells) ranging 
from n= 40 to 211. Error bars represent SEM values, ‘**’ represents p<0.01, and ‘*’ 
represents p<0.5. 
In the co-culture model, the peak calcium response was found to be at 15% and 
63%, respectively, for controls and cells stimulated with inflammatory stimulus. These 
values show that calcium response for co-culture lies in between the two individual cell 
cultures and shows 76% inhibition compared to the BMVECs monoculture and a 49% 
increase compared to astrocyte monoculture. Thus, the results indicated that the 
stimulated cells show significantly higher calcium influx in all conditions i.e., 
monocultures of BMVECs and astrocytes as well as their co-culture, compared to the 
cells at normal physiology (controls). The BMVECs culture shows excessive calcium 





observed in neurons when treated with TNF (178), which is caused by the expression of 
voltage-sensitive calcium channels in neurons, leading to hyperactive calcineurin activity 
and synaptic depression. This dyshomeostasis of Ca++ in BMVECs was balanced in the 
presence of astrocytes in the co-culture model, as the peak calcium response for 
stimulated co-culture model was enhanced compared to the co-culture controls but was 
significantly inhibited compared to the stimulated BMVECs culture. These results 
indicate that astrocytes have a role in balancing the excessive calcium influx in BMVECs 
during inflammation. 
6.3.2.2 Cellular Population Response to Ca++ influx 
The stimulated BMVECs cells had a mean total of 122 cells per ROI, which is 
significantly higher compared to 83 cells for controls per ROI analyzed (Figure 6.10A).  
Out of the  cells present in the ROIs, a mean of 94% (687 of 731) of the stimulated cells 
responded to the ATP stimulus, while a mean of 87% (432 of 496) control cells responded 
to ATP (Figure 6.10B). These results suggest that the high Ca++ influx in BMVECs is 
supported by a significantly higher percentage of cellular response. The astrocytes also 
showed a higher number of cells per ROI for cells stimulated with the inflammatory 
stimulus with an average number of 75 cells for stimulated and 56 for control conditions 
(Figure.6.10A). These average numbers of cells per ROI for astrocytes were significantly 
smaller than the values observed for BMVECs.  As astrocytes are normally larger and 
flatter than BMVECs, less cells cover larger surface area under their normal physiology. 
A high percentage of cells responded to the ATP stimulus with a mean of 96% of cells 
(289 out of 301) in  ROI responding to ATP, which is significantly high compared to 





(Figure.6.10B). These results verify that the cellular response to ATP is significantly 
high for stimulated conditions in both BMVECs and astrocytes with higher calcium 
influx as wells as a larger population of cells responding to the ATP stimulation. 
 
 
Figure 6. 10: Results for A) Mean number of cells present B) Percentage mean of 
cells responding to ATP stimulus; per ROI for BMVECs, astrocytes, and co-
culture model. Data represent the averages of  N= 3 experiments with two wells 
per condition, and no. of samples (cells) ranging from n= 40 to 211. Error bar 
represents SEM values, ‘**’ represents p<0.01, and ‘*’ represents p<0.5. 
 
 
In line with the BMVECs and astrocyte culture, the co-culture model also showed 
a higher cell count per ROI with an average of 125 cells for stimulated cells compared to 








the experiment helps to increase the proliferation of cells in the system as shown in 
Section 4.3.3.  An interesting observation in the co-culture model was found in the case 
of the percentage of cells responding to the ATP stimulation. The co-culture shows no 
significant difference in percentages of cells  that responded to ATP stimulation as the 
averages are around 77% for both control (428 out of 556) and stimulated (576 out of 748 
cells) conditions, unlike BMVECs and astrocytes, where significantly higher percentages 
of stimulated cells responded compared to controls. Further, the percentage of cells 
responding to ATP also lies in between the percentages observed for BMVECs and 
astrocytes. These observations reinforce the results that presence of astrocyte provides 
negative feedback to the high calcium response observed in BMVECs as an act of 
balance of inflammatory effect on overall cellular networks in the culture and not merely 
the action of a certain population of cells. 
A total number of cells, frames, and data points, as shown in Table 3, were 
recorded for BMVECs, astrocytes, and co-cultures for studying the calcium response in 
BBB during inflammation. 
Table 3: Database used for studying calcium response in BBB cells and their co-culture 
model when stimulated with the inflammatory response   (100 ng/ml of TNF +5µg/ml of 
LPS) 
 
Data Point Frame Total cell 
BMVECs Culture 157,855 1567 1725 
Astrocyte cultures 42,351 661 637 








6.4 Conclusion and Discussion 
Calcium and neuroinflammatory signals exhibit cross-talk and bidirectional 
interactions, though they are distinct in many ways (178) and NO is one such 
inflammatory signal.  Figure 4.1 showed that even the astrocytes, the low NO producing 
cells in the system, can produce 5 µM of sodium nitrite (NaNO2).  This research finds 
that treatment of BMVECs with  5 µM of sodium nitrite  in the presence of d-serine, can 
produce enhanced calcium response and a significantly higher number of calcium 
oscillations, while the same treatment in astrocyte does not produce any significant 
difference in the calcium response.  Coactivation of NMDA receptor by glutamate and d-
serine increased vasodilation in eNOS dependent mechanism (177), and in our 
experiment we observed enhanced calcium response to NO and d-serine treatment in 
endothelial cells, thus showing the modulatory activity of  NO for calcium signals is 
possibly mediated by NMDA activation in endothelial cells which might be central to 
NVC since intracellular Ca++ has been known to drive NVC. Enhanced calcium influx at 
BBB may modulate barrier permeability, and therefore it might be a cue on NO-mediated 
BBB permeability(179). 
When the calcium response was studied in presence of inflammatory stimulus in 
cells, BMVECs showed excessive calcium influx in stimulated cells, indicating calcium 
dysregulation in cells which is a determining factor for brain cell death and degeneration. 
This uncontrolled increase in calcium was significantly inhibited in the coculture model 
by the presence of astrocytes, indicating that astrocytes can produce a negative feedback 
mechanism to the calcium dysregulation in BMVECs during inflammation, which can 







NANOMATERIALS AS CARRIERS FOR 




Neurological and mental disorders are some of the most poorly treated diseases 
currently, impacting the lives of people of all ages and growing the chances of premature 
death.  Epilepsy, Alzheimer’s, Parkinson’s, multiple sclerosis and ALS are common 
examples of neurological disorders that have affected 1 billion of the human population, 
with nearly 1 out of 6 people suffering from these diseases (121). Thus, if these disorders 
could be treated through various techniques such as nanotechnology, up to 70% of 
diagnosed patients could be cured (180–182). 
The brain microvascular endothelial cells (BMVECs) in the blood-brain barrier 
constitute the tight junction proteins in between the cells which along with other unique 
features of BMVECs, as stated in Section 2.1.1, provide selective permeability to BBB. 
Thus the BBB prevents the entry of pathogens and other toxic substances into the brain, 
but at the same time, prevents most potential drugs against neurological and mental 
disorders to cross the barrier and readily reach into the brain tissue (21). In this research, 
we studied the potential application of naturally available, environmentally friendly 
halloysite nanotubes (HNT) as a carrier for drug delivery across the endothelial cells. 





lumen. They are formed by 10–15 revolutions of 0.7 nm thick kaolin aluminosilicate 
sheets with diameters at a range of 50 and 60 nm, lumen diameters of 12–15 nm, and 
lengths of 500–900 nm (183,184). The outer surface of HNTs is composed of SiO2, and 
the inner surface is composed of Al2O3, which are oppositely (negative/positive) charged 
in the pH range of 3–9. The HNT structure shown in (Figure 7.1) shows how payloads or 
drugs can be loaded in the positively charged lumen that is efficient in adsorbing 
negatively charged drug molecules spontaneously.  
 
Figure 7. 1: A TEM and SEM image of halloysite nanotubes (a and b). Schematic of 
halloysite nanotube depicting characteristics and dimensions of halloysite nanotubes 
(c and d) (18) . 
This chapter uses fluorescence microscopy to study binding and penetration of 
HNTs tagged by fluorescent rhodamine B isothiocyanate dye (RITC) into BMVECs for 
better visualization of cellular interaction or penetration of HNTs and their delivery 






ionophore (185), for brain cell stimulation to monitor real-time calcium transport across a 
membrane that exhibits the real-time delivery properties of HNT-ionomycin 
formulations. Ionomycin was selected for loading and delivery studies because it has 
well-known antibiotic property and might be able to induce cancer cell death and inhibit 
proliferation (186,187). All experiments related to HNTs were performed in collaboration 
with Mahdi Saleh from Dr. Lvov’s lab, where part of the work related to  HNTs 
processing and loading with RITC and ionomycin was performed by him. This chapter 
also includes a brief report on cellular uptake of a novel cationic peptide ‘L57’ in 
BMVECs cells to explore their potential as a carrier across blood brain barrier (188). The 
experiments related to ‘L57’peptide were performed in collaboration with Jolin 
Rodrigues from Dr. Murray’s lab.  
7.2 Materials and Methods 
Figure 7.2 shows the overall experimental layout for studying HNTs loaded with RITC 
and ionomycin for their potential as drug delivery vehicle across BBB by using 
fluorescence microscopy, calcium imaging system and MTT assay. The following 






Figure 7. 2: Schematics showing loading clay nanotubes with fluorescent rhodamine 
(RITC) and ionomycin and treating the endothelial cells with the loaded nanotubes. 
[1] HNT-RITC route monitored with Fluorescence Microscopy, [2] HNT-Ionomycin 
route monitored using Calcium Imaging System and [3] Cytotoxicity assessment of  
HNTs using MTT assay. 
7.2.1 Preparation of HNT-RITC and HNT-Ionomycin Formulations  
Three samples of HNTs, loaded as 10 mg halloysite/1 mL DI water per 0.5, 1, and 
2 mg of RITC were obtained from Dr. Lvov’s lab at Louisiana Tech University. 
Halloysite samples were prepared by loading RITC and ionomycin through stirring, 
centrifugation, and sonication. For HNT-ionomycin formulation, 20 mg of HNTs were 
stirred with a 1 µM final concentration of ionomycin for 24 hours. The solutions were 
then sonicated and vortexed for 1 min, then mixed on a stir plate for 24 h at room 
temperature. The mixture was washed once by centrifugation at 2500 RPM for 2.5 min 
and then dried at 70 ºC for 24 h. The mixture was then washed with sterile water by 





placed in a vacuum for 24 h to remove the excess solution. Samples were then 
characterized by the zeta potential analyzer, which displays the surface charge and 
thermogravimetric analysis, allowing us to calculate the loading percentage.  
7.2.2 Cell Treatment with HNT-RITC Formulations 
The BMVECs were isolated from cortical glial culture as mentioned in Section 
3.1.  BMVECs thus obtained were plated at the density of 10k per mL in 48 well cell 
culture plates and grown in vitro at 5% CO2 and 37 ºC. When the cells reached ~60% 
confluency, they were treated with 10 µg/mL of three different samples of HNT-RITC 
formulations, each with a loading ratio of 1:20,1:10 and 1:5. Cells treated with media 
alone were used as controls for determining cellular toxicity and change in morphology. 
Cells treated with RITC alone were used as positive controls for fluorescence. Cells 
treated with empty halloysite tubes were used as negative controls for both BMVECs 
stimulation and RITC experiments. The treated cells were incubated for three different 
time points, 30 mins, 4 hours, and 24 hours, to analyze the efficiency of fluorescent 
tagging and delivery of RITC from HNTs over time.  
7.2.3 Digital Microscopy  
After the predetermined incubation period with HNTs loaded with RITC, all the 
controls and experimental wells were washed twice with 250 µL of warm 1X PBS, which 
was replaced by 300 µL of phenol red-free RPMI media, warmed at 37 ºC, before 
imaging them live using Digital Microscopy (Leica DMI 6000B). Three images per well 
were captured for 3 wells per condition of treatment for 3 different experiments to 
observe the binding and penetration of halloysites in the BMVEC cells and the delivery 





7.2.4 Cell Stimulation with HNT-Ionomycin Formulations 
For BMVECs stimulation with HNT-ionomycin formulations, cells were grown in 
vitro at 5% CO2 and 370C until they reach confluency ~70%. Two concentrations 
(10 µg/mL and 50 µg/mL) of HNT-ionomycin formulations were used to stimulate the 
cells. Empty halloysite nanotubes (50 µg/mL) as negative controls and 1 µM of 
ionomycin as positive control were also used for stimulating the cells. Figure 7.3 
presents a schematic for BMVECs cell stimulation using HNT loaded with ionomycin 
and signal recording using calcium imaging system. 
 
Figure 7. 3: Schematics illustrating the loading of ionomycin inside the lumen of 
halloysite nanotubes and stimulating cells on top of the calcium imaging system for 
capturing real-time calcium events due to delivery of ionomycin from HNTs into the 
brain endothelial cells. 
The cells were loaded as mentioned earlier in Section 6.3.2.1 and Appendix C.7. 
The cells were incubated with loading solution for 1 h at 5% CO2  and 37 ºC in a 
humidified incubator and then with 500 µL of recovery solution for another 1 hour. The 
recovered cells were then stimulated with halloysite loaded with ionomycin (10 and 50 
µg/mL), halloysite alone (50 µg/mL), ATP 100 µM, and ionomycin 1 µM at different 
instances depending on the experimental design. Real-time intracellular calcium (Ca++) 
change caused by ionomycin transport across the cell membrane was recorded by 





images were then used for measuring and analyzing calcium fluorescence intensity as 
mentioned in Section 6.2.3.2. This technique uses the change in fluorescence intensity as 
the function of time as a measure for quantifying calcium changes in cells which 
corresponds to the delivery of ionomycin from halloysite nanotubes. 
7.2.5 MTT Assay 
The MTT assay is described in Section 5.2.4, and Appendix H.  
7.2.6 Cellular Uptake of Fl-L57 Peptide  
L57 peptide was purchased from Biomatik (Cambridge, ON, Canada).BMVECs 
and astrocytes were plated at a density of 10,000 cells per well and grown at 37 ºC and 
5% CO2. When the cells reach ~50 to 70% confluency, cells were treated with FITC 
(fluorescein isothiocyanate)-labeled L57 (FL-l57)  peptide at 3, 10 and 30 µM 
concentrations for 4 hours, and uptake was visualized by taking images under 
fluorescence microscope (Leica DMI 6000B). 
7.3 Results 
7.3.1 Cell Treatment with HNT- RITC Formulations 
Halloysite binding and penetration into the endothelial cells were visualized as 
red fluorescence concentrated within the cells, Figure 7.4. The addition of RITC dye 
alone did not color the cell's interior within 30 min of treatment, while the dye-loaded 
halloysite bound or penetrated the cells and started releasing the dye inside the cells, 
coloring them red. Within a 4-h time frame, RITC and RITC-HNT both showed cells 
with more fluorescence compared to the same samples in the 30 min exposure time 
(Figure 7.5). Furthermore, RITC-HNT formulations displayed greater fluorescence 





loading of RITC in HNTs shown are 5 wt % (1:20) and 20 wt.% (1:5), and the 
concentration used for RITC alone controls shown is equivalent to 20 wt % HNT 
samples.  
The small bright dots seen in the images of Figures 7.4, 7.5, 7.7 and 7.8 are the 
aggregated halloysite tubes that contain RITC.  HNT-RITC aggregation is displayed 
mostly along the cellular membrane and inside the endothelial cells as indicated by 
nuclear exclusion. Therefore, halloysite nanotubes can encapsulate, transport, and slowly 
release the dye (or drugs as we will show with an example of ionomycin) over 24 hours. 
An important consideration is that the surface of the halloysite was not modified with any 






Figure 7. 4: Fluorescent (Left) and Phase (Right) images of endothelial cells treated 
with halloysite nanotubes loaded with RITC dye after 30 mins of exposure, for 
samples with loading ratio 1:20 (A-B),  loading ratio 1:5 (C-D) and RITC only (E, 






Figure 7. 5: Fluorescent (Left) and Phase (Right) images of endothelial cells’ 
treatment with halloysite nanotubes loaded with RITC dye (samples) after 4 hours 
of exposure for cells treated with  HNT-RITC( loading ratio 1:20) [A-B], cells 
treated with  HNT-RITC( loading ratio 1:5) (C-D) and cells treated with RITC 






Figure 7. 6: Fluorescent (Left) and Phase (Right) images of endothelial control 
cells after 4 hours of exposure - with no treatment [A-B], and treated with 
halloysite alone [C, D]. Magnification 200X,scale bar=100µm 
  
Results for the 24-h treatment showed more profound fluorescence in both 
conditions but RITC-loaded halloysite delivered more dye into the cells at every period as 
compared to just the dye alone (Figure 7.7). Images at a time point of 24 h displayed the 
nanotubes distribution more evenly over the cell interior, still contained within the cell 
body (Figure 7.8G). RITC-HNT are concentrated in some smaller spots of ca. 1 µm 
dimeter, which may be the nuclear surrounding, as was found for MCF-7 cells treated with 
halloysite (Vergaro et al., 2010). Throughout the trials, we detected a nuclear exclusion, 
extended length of fluorescence, and that the tubes did not stress or kill the cells. The clay 







Figure 7. 7: Fluorescent (Left) and Phase (Right) images of endothelial cells’ 
treatment with halloysite nanotubes loaded with RITC (samples) dye after 24 hours of 
exposure for cells - treated with  HNT-RITC( loading ratio 1:20) [A-B], treated with  
HNT-RITC (loading ratio 1:10) [C-D], treated with  HNT-RITC( loading ratio 1:5) 
[E-F] and treated with RITC alone(control) equivalent to loading ratio 1:5. 





After cell fixation (4 days), cells treated with dye only were washed away with only 
minimal fluorescence remaining on the cells.  The HNT-RITC treated cells still 
showed significant fluorescence up to 11 days of observation, indicating a prolonged 
delivery of the dye from the clay nanotubes (Figure 7.8). 
 
Figure 7. 8: Fluorescent Images of endothelial cells treated with halloysite 
nanotubes loaded with RITC dye after 11 days of exposure, for samples with 
loading ratio 1:10 (A) and RITC only (B).Magnification 200X,Scale bar=100µm 
 
7.3.2 Delivery of Ionomycin – Halloysite Formulations into BMVECs 
 
Figure 7. 9: Images captured in the calcium imaging system for BMVECs at (A) no 
stimulation (baseline); (B) peak stimulation by 50 µg/mL of empty halloysite nanotube, 






Figure 7.9 shows us the images captured during real-time calcium imaging of 
BMVECs before and after stimulation with empty HNTs and HNTs loaded with 
ionomycin. A series of images captured at the interval of 4 seconds each were analyzed to 
obtained calcium signals, as shown in Figure 7.10. 
 From real-time calcium imaging, the cell's response to ionomycin had a spiked 
increase in Ca++, which decayed quickly due to clearance by cells as shown in baseline 
(Figure 7.10A). When ionomycin was encapsulated with halloysite, we achieved a higher 
response of Ca++ for the same concentration (1 µM) loaded that was also used for the 
control, resulting in a gradual rise in Ca++, which remained at higher level for a longer 
period until it was diluted by the addition of any other stimuli. This increase of Ca++ 
indicates the gradual and prolonged transport of ionomycin through halloysite across the 
cell membrane (Figures 7.10B and C).Cell stimulation with empty halloysite nanotubes 
led to only a small response (Figure 7.10D). To ensure that the cells were healthy and 
responding normally to other physiological stimuli, cells were tested with ATP, a well-
known stimulator for BMVECs (Figures 7.10E). Cells that responded to ATP showed a 
significant peak that is normally observed for BMVECs, ensuring normal physiology of 
the stimulated cells . Each experiment was ended with ionomycin stimulation to 
demonstrate that the cells were still responsive to Ca++ changes, ensuring no cell death, 
and avoiding the occurrence of false signals during the experiments.  Ca++ peak analysis 
presented in Figure 7.10 indicates that stimulation by ionomycin (positive control) shows 
an instant peak of Ca++ that decays quickly compared to HNT-ionomycin nanocapsules 
(10 and 50 µg/mL), which shows a gradual influx of Ca++ and a higher delivery of 





halloysite alone can produce a slight Ca++ response, significantly less compared to HNT-
ionomycin formulations, that show significant increase in Ca++ response for the use of 10 
µg/ml, which can be enhanced further with the stimulations by higher concentrations of 
HNT-ionomycin.  
 
Figure 7. 10:  Ca++ peak intensity obtained for different stimulation on BMVECs, in 
the horizontal axis is the image number indicating periods with a total range of 4 s 
each (1 image no. = 4 s); and in the vertical axis is the normalized values for 
fluorescence intensity corresponding to calcium activity (A) stimulated by ionomycin 
(Iono) 1 µM (positive control); (B)stimulated by 10 µg/mL and 50 µg/mL of HNT- 
ionomycin (sample tested);(C) stimulated by 50 µg/mL of HNT- ionomycin (D) 
stimulated by 50 µg/mL of empty HNTs (negative control)  and (E) stimulated by 
ATP, a well-known Ca++ stimulator (positive control indicating healthy cells), 
followed by HNT-ionomycin formulation (10 µg/mL) showing the comparison 
between the Ca++ responses of physiological stimulation (ATP) and HNT-ionomycin 
formulation for the same cells. The X-axis represents time and shows total time the 







7.3.3 Statistical Analysis of Calcium Response to Different Stimuli  
The graphs in Figure 7.10 show signals obtained for only 3 cells for each 
condition for simplification and clear representation of the data. The number of cells 
captured per frame for a condition being tested in an experiment act as a ROI, and it 
ranged from 41 to 140 cells. After obtaining the calcium signals for different 
stimulations, the Ca++ fluorescence intensity data as a function of time were used to 
extract the various information as shown in Figure 7.1,1 namely percentage of peak Ca++ 
response above the baseline (Figure 7.12), time taken for the stimuli to reach the peak 
response (Figure 7.13), and the number of cells that responded to the stimuli (Figure 
7.14). Overall, 1,232 cells were analyzed for the results reported for calcium imaging. 
 
Figure 7. 11: The signal explanation scheme that elucidates various parameters 
analyzed for the calcium signals recorded after the stimulations of cells (18). 
The results for calcium signal analysis shows that the increase in peak calcium 
response above the baseline was 120% for HNT-ionomycin (50 µg/mL), and it was 
significantly greater than for ionomycin alone (positive control) which was at 82%. The 
halloysite (negative controls) showed a slight Ca++ response of 16% above baseline. The 
results that the nanotubes alone can cause some Ca++ response suggest that some form of 





networks is served by the signaling molecule, calcium. For ATP stimulation the peak 
response was 40% above baseline, which indicates ATP response in normal physiological 
conditions of cultures used (Figure 7.12). 
 
Figure 7. 12: Increase in peak calcium response in percentage for each stimulus used 
to stimulate the BMVECs, averaged over three experiments (N=3) for each 
stimulation, with n= 41 to 140 cells analyzed per experiment. Error bar represents the 
standard deviation between the experiments and “***” represents p<0.001. 
Figure 7.13 represents the time taken for the cells to produce the peak calcium 
response. It tells us how delayed or instantaneous the peak response was, indicating the 
delivery properties of halloysite clay nanotubes. The duration of release until peak 
calcium response after the stimulation was found to be 80 s for the nanoclay loaded with 
ionomycin at 10 µg/mL, 54 s for halloysite loaded with ionomycin at 50 µg/mL, and 66 s 
for 50 µg/mL halloysite alone. This result, along with results in Figure 7.10 A, B and E, 
explains that a low concentration 10 µg/mL HNT-ionomycin formulation is enough to 
enhance delivery of ionomycin for a prolonged time as compared to ionomycin itself. A 





better achieved with the use of lower concentrations. In contrast, the duration was very 
short for ionomycin 1 µM at 13 s and ATP at 16 s. The duration was found higher for the 
halloysite-loaded and unloaded samples as compared to ionomycin and ATP in their 
soluble forms. This higher duration indicates delayed diffusion from the nanotubes 
caused by the faster release of soluble ionomycin and ATP. Overall, the halloysite loaded 
with ionomycin showed delayed and gradual release of ionomycin into the cells and once 
it reaches the peak response it continues to diffuse for a prolonged time which is expected 
to be up to 24 hours as was observed for the nanotubes loaded with RITC (Figures 7.7).  
A 24-hour treatment of BMVECs with ionomycin concentration of 1 µM that was used 
throughout the experiment did not show any cytotoxicity to the cells. 
 
Figure 7.13: The time taken (seconds) to reach the peak calcium rise after a 
stimulation in the BMVECs, indicating how delayed the peak response is. The results 
are averaged over three experiments (N=3) for each stimulation, with n = 41 to 140 
cells analyzed per experiment. Error bar represents the standard deviation between the 






Figure 7. 14: The  percentage of BMVECs responding to a particular stimulation. 
The results are averaged over three experiments (N=3) for each stimulation, with 
n= 41 to 140 cells analyzed per experiment. Error bar represents the standard 
deviation between the experiments and “***” represents p<0.001. 
 
Figure 7.14 represents the percentage of cells that responded to the given 
stimulus in an experiment. A higher number of cells responded to the HNT – ionomycin 
formulation with 97% for a concentration of 10 µg/mL and at 92% for 50 µg/mL, while it 
was 65% for 50 µg/mL halloysite alone, 72% for 1 µM ionomycin, and 76% for 100 µM 
ATP. This result indicates that all the parameters discussed here are supported by a high 
response of cells, but the data specifically displays a higher value in the loaded samples 
compared to the other conditions tested.  
7.3.4 Lack of Toxicity Response of Halloysite Nanotubes in BMVECs 
An MTT assay was performed 24 hours after treatment of the BMVECs cells 
plated at 10k per ml when they reached 60% confluency to assess cell metabolism as the 





affect the cell metabolism in BMVECs and hence show no significant sign of toxicity as 
the cellular metabolism was observed to be in a proximity of 1 to 2% more or less for the 
treatment of 10, 25 and 50 µg/ml of HNTs, compared to control cells treated with media 
alone (Figure 7.15). The positive control for toxicity, where 6 µg/ml of CuNPs were 
added to the cells, showed inhibition of cell metabolism by 27% within 24 hours. 
 
Figure 7. 15: Graph showing results for cytotoxicity testing of three different 
concentrations (10,25 and 50µg/ml) of HNTs indicating no significant toxicity 
imparted by HNTs on BMVECs by 24 hours of treatment. CuNPs were used as a 
positive control for toxicity. Data represents an average of three experiments (N=2) 
with triplicated wells(n=3). Error bar represents SEM values, “***” represents 
p<0.001 and “*” represents p<0.05. 
7.3.5 Cellular Uptake of Fl-L57 Peptides 
Cells treated with Fl-57 peptides showed diffused staining throughout the cells for 
both BMVECs and astrocytes. BMVECs incubated with 30 µM of Fl-57 exhibited 
saturation of fluorescence.  BMVECs showed significantly higher fluorescence and low 
cytotoxicity and therefore significantly higher uptake of Fl-57 peptides, as shown by 
Rodrigues et al. (186). Astrocytes showed comparably less fluorescence and therefore 






Figure 7. 16: Fluorescence (Left) and phase (Right) images of cells treated with 10 
µM of Fl-L57 peptides for BMVECs (A-B) and 30 µM of Fl-L57 peptides for 
astrocytes (C-D) (188). Magnification=200X, scale bar=100 µm. 
 
7.4 Conclusions 
Halloysite nanotubes show great potential in delivering drugs effectively to the 
brain as they were able to bind to the BMVECs and slowly release drugs over various 
periods ranging from minutes to hours with no signs of toxicity to the endothelial cells of 
brain micro vessels. The ability of halloysite to show enhanced, gradual, and prolonged 
calcium response in brain microvascular endothelial cells when stimulated with the calcium 
ionophore- ionomycin, compared to the use of ionophore alone (non-encapsulated) showed 
real-time delivery characteristics of HNTs across the brain cell. Stimulation of BMVECs 





recently discovered information suggests an approach to treating brain cancer cells through 
drug delivery based upon the evidence suggesting inhibitory potential of ionomycin on the 
cancer cells and its use as a chemosensitizer. We confirmed a delayed and prolonged 
diffusion of the drug delivery mechanism when the cell probes (ionomycin+ RITC) were 
loaded onto halloysite nanotubes. This loading provides a sustained delivery strategy for 
drug penetration across the blood-brain barrier. Like HNTs, the lack of cytotoxicity and 
high uptake of Fl-57 peptide observed on BMVECs exhibit the potential of the peptide as 










CONCLUSION AND FUTURE DIRECTIONS 
 
A large body of evidence suggests that astrocytes play a critical role in inducing 
BBB attributes and functions by assisting in the proper expression and assembly of 
intermolecular tight junctions, transporter proteins, and enzymatic pathways 
(147,189,190). Astrocyte-secreted factors like VEGF, TGF-β, angiopoietin, glial-derived 
neurotrophic factor are also known to be responsible for modulating BBB functions (4). 
Hence, this research develops a co-culture model of BMVECs and astrocytes to create an 
optimized BBB microenvironment while maintaining cellular communication to assess 
the contribution of each cell type in the overall inflammatory response of BBB, 
specifically for NO and calcium activity of cells, considering the physiological and 
pathological significance of NO and Ca++ signaling in the brain. It also compares the 
overall response to the monocultures of each cell type. When induced with the 
inflammatory stimuli, the BMVECs cells produced an enormous amount of NO, in 
contrast to the astrocyte cells which showed only a slight increase initially which 
saturated over time. The cellular interaction between astrocytes and endothelial cells in 
the co-culture model significantly reduced the NO synthesis compared to the BMVECs 
monoculture, thus suggesting that astrocytes provide negative feedback to extreme NO 





peroxynitrite-related neurotoxicity or immune breach and BBB disruption related 
neurological disorders.  
This negative feedback function of astrocytes was further explored for the Ca++ 
activity in the inflammation-induced co-culture model and compared with the Ca++ 
activity in the individual cell types under normal physiology and when stimulated with 
the inflammatory signal. A significant Ca++ dysregulation was observed in BMVECs 
cells, which is generally an indication of brain cell death and degeneration and which was 
balanced by the presence of astrocytes in the co-culture model, thus verifying the 
negative feedback potential of astrocyte cells to the enhanced calcium activity in 
BMVECs during inflammation. Ca++ changes were also measured for BMVECs cells by 
treating them with a NO donor (NaNO2), to assess the effect of NO in the calcium 
activity of BMVECs, in the presence and absence of d-serine, which showed significantly 
enhanced calcium response and oscillations in the BMVECs due to NaNO2 in presence of 
d-serine. 
Taking into consideration the huge research interest in therapeutics related to 
exogenous NO delivery or NO catalysis in vivo for biomedical applications, this research 
investigated the potential of CuHARS in NO catalysis in BMVECs cells during normal 
physiology in presence of cystine nitroso thiol (CysNO) and when induced with 
inflammation. CuHARS produced significant NO in presence of CysNO involving 
constitutive eNOS in BMVECs, which is known for its beneficial role in the body while 
it inhibited the iNOS produced during inflammatory conditions often known to have 
harmful impacts in the body. Further CuHARS increased BMVECs metabolism and 





showcasing an extensive potential in drug delivery application in CNS. The HNTs loaded 
with RITC and ionomycin separately, showed gradual and prolonged delivery of RITC 
and ionomycin over time in BMVECs cells with no toxicity imparted to the cells like the 
cell penetrating peptide (CPP) Fl- L57, which showed high uptake and no toxicity to the 
cells. These results suggest HNTs and Fl- L57 as promising carriers for drug delivery 
across BBB.  
Figure 8.1: Schematics explaining the overall project summary  
Although the testing of carriers on 2D in vitro cultures of BBB cells provided 
evidence of biocompatibility and effectiveness in uptake and delivery of the materials to 
the cells, questions about the carriers’ ability to bypass the inherent resistance of BBB 
and deliver the payload to localized regions in brain remain to be explored. A multilayer 
membrane of endothelial and astrocyte cells maintained across a permeating barrier as 
shown in Figure 8.2 that closely mimics biological and structural complexities of the 





developments on CNS drug delivery strategies implementing potential carriers HNTs, 
CuHARS, CPPs and other nanomaterials.  
 
Figure 8.2: Schematic presenting future direction towards testing permeabilities of 
delivery vehicles (CuHARS, HNTs and CPPs) and their payload across blood brain 







APPENDIX A  
 
A.1 TNF and LPS Stimulation on BMVECs 
 
Figure A. 1: Bar graph showing the concentration of NO released by BMVECs 
controls, controls inhibited by 1mM L-NAME (LN), BMVECs stimulated with the 
inflammatory stimulus  (a combination of 100ng/ml of TNF+ 5µg/ml of LPS), 
stimulated cells with LN inhibition, BMVECs treated with LPS alone (5µg/ml)  and 
TNF alone (100ng/ml) for 2,4 and 6 DIV indicating that NO significant NO is 
produced when cells are stimulated with  LPS alone or TNF alone. Data represent 
averages for three experiments(N=3) with four wells (n=4) per condition. Error bars 











A.2 Lumen Quantification Using Image Pro 7 
 
 
Figure A. 2: Quantification of lumen formation in BMVECs – A) Controls and B) 
Stimulated with inflammatory stimulus on 6 DIV, using Image-Pro 7 software. 
 
A.3 Cytotoxicity on BMVECs with CuHARS Treatment 
Two cell densities 3k and 6k cells per ml were plated on 48 well plates and incubated at 37 
ºC and 5% CO2 for 3 days to provide them enough time for binding and growing on the 
well plates. Both cell densities were treated on day 4 with 3 µg/ml and 6 µg/ml CuNPs 
(positive controls) and 6µg/ml of CuHARs. Cell toxicity was observed under the 






Figure A. 3: Comparison of Cytotoxicity between CuHARS and CuNPs on BMVECs 
using Diff Quik staining technique after 24hours of treatment. The left panel shows 
results for treatment in cells plated at 3k per mL and the right panel shows results for 
cells plated at 6k per mL for -Controls (A-B), treated with 3µg/ml of  CuNPs (C-D), 
treated with 6µg/ml of CuNPs (E-F) and treated with 6µg/ml of CuHARS (G-H), 











Figure A. 4: Total count of cells (Nuclei) analyzed from Diff Quik staining for 
treatment of 3µg/ml and 6µg/ml of CuNPs Vs 6µg/ml of CuHARS, showing higher 
cell count at both 3k and 6k cell density and thus significantly low toxicity in 







APPENDIX B  
 
IMAGE-PRO PLUS VERSION 7.0 
B.1 Calculating the Area of GFAP Staining from the Image 
1. Insert the dongle (special security plug) that comes with Image-Pro Plus to unlock the 
program. 
2. Open Image-Pro Plus 7.0. A dialog box ‘Macro Browser’ appears. Click Done. 
3. Go to File  Open  Select the image. 
4. Go to Measure  Count/Size  Choose ‘Manual’  Click ‘Select Colors’  A 
dialog box appears. Click ‘Color Cube-Based’  Select Class ‘1’  Under Options, 
Select Sensitivity ‘4’  Pick ‘color picker tool’. Then click on the indigo blue color 
staining (Start selecting the color from lightest to darkest)  Under Preview, select 
‘Current Class’  Change to ‘Class Color on Black’ from ‘Class Color on Transparent’ 
 Select ‘Apply Mask’  Click ‘OK’. 
5. Now choose ‘Automatic Bright Objects’ Click ‘Count’. The white area gets selected. 
6. Go to ‘Measure’  Click ‘Select Measurements’  Choose ‘Area’  Click 
‘Measure’. 
7. Go to ‘View’  Click ‘Measurement Data’  Choose ‘Sort Down’. 





Figure B.1: An example of image analysis to calculate the area of GFAP- staining 











APPENDIX C  
 
CELL CULTURE AND MEDIA PREPARATION 
C.1  Rat Primary Cervical Disarticulation:  
Use a fresh 50 ml tube with 15 ml media and 750µl penicillin-streptomycin (PS) 
to collect tissue.  
C.1.1 Materials Needed for Dissection:  
1. Large petri dish  
2. Diapers  
3. Empty yellow-tip containers  
4. Plastic bag  
5. Cervical Scissors  
6. Micro-scissors  
7. Curve tip scissors  
8. Small tip forceps  
9. Large forceps  
10. Small spatula  
11. Full wash bottle with 70% Isopropyl alcohol  
12. 50ml centrifuge tubes with 40ml basal media eagle (BME)  
13. 50ml centrifuge tube with 10ml BME and 0.05% PS (one for every 7 pups) 
14. Box of gloves  





16. Beaker of ice 
C.1.2 Set-up for Dissection:  
1. Soak the dissection instruments with 70% isopropyl alcohol in a container. 
 2. Place the pups in the yellow container and set them on one end of the 
dissection table.  
3. Place three diapers on the dissection table. 
 4. Place one large petri dish under the microscope and pour ~10ml BME and PS 
into it. 
 5. Place another petri dish about seven inches away from the dish under the 
microscope to be used for waste.  
6. Place and keep the plastic bag near the diapers.  
7. Place the 50ml centrifuge tube holder on the dissection table next to the 
alcohol.  
8. Place the wash bottle next to the utensils. 
 9. Keep the basal media, gloves, and other supplies on the cart.  
10. Place over-head lighting and stereoscope in position above the centered dish.  
C.1.3 Dissection Protocol:  
1. Put on a pair of gloves. 
 2. Remove one pup from the box by pinching the skin above the spine near the 
lower back and set the pinkie on a diaper. 





4. Quickly set cervical scissors behind the ear being cautious of paws and make 
one very quick and decisive cut. (Dip scissors in alcohol and place it on a clean 
diaper)  
5. Blot the head at the point of disarticulation on a diaper and discard the body in 
the plastic bag. 
 6. Using the micro-scissors, cut the skin in an upward motion then dip scissors in 
alcohol (This should expose the skull). 
 7. Cut the skull using the same upward motion (this should expose the brain) 
 8. Using large forceps, curl back both sides of the skull to better expose the brain 
then use a spatula to scoop out the brain into the basal media in the petri dish.  
9. Remove the cerebellum at the demarcation line and place it in the waste dish. 
10. Keep the brain in place with large forceps and remove meninges and blood 
vessels with small forceps. Place the waste into the waste dish. 
 11. Once all blood vessels and meninges are removed, place tissue into a 50 ml 
tube.  
12. Repeat steps 2-11 until all pups are sacrificed.  
13. Discard all waste into the freezer room and clean all utensils. 
C.1.4 Materials Needed for Tissue Culture:  
1. T25 cell culture flask 
 2. Bucket of ice  
3. Neuronal Culture Media 





C.1.5 Cell Harvest Protocol:  
1. Aspirate harvested brain tissue with a 10ml pipette into a 15 ml tube.  
2. Add 4ml of complete NCM and 1ml trypsin brain tissue then triturate about 15 
times.  
3. Let the brain tissue settle by placing it into a large beaker of ice for 5 minutes. 
4. The supernatant contains the neuronal cells. Remove the supernatant and place 
it into another sterilized 15 ml centrifuge tube and place on ice.  
5. Repeat steps 2-4 two more times.  
6. Centrifuge and follow protocol to count and plate cells in the cell culture flask. 
C.2 Protocol for Isolation of BMVECs from Glial Cells 
C.2.1 Materials Required 
1.Primary culture (washed at least 1 time) 
2.Puromycin (10mg/ml) 
C.2.2 Protocol 
1. Add 3ug/ml concentration of puromycin to the primary culture 
For 3 flasks, perform the following dilution: 
Add 4.5ul of puromycin to 15ml astrocyte media. Mix well by inverting the tube. 
Suck out the media from flasks. Add 5ml of mixed solution to each flask 
Place the flasks in the incubator for 48h 
Suck out all the media and dead cells. 





C.3 Rat Brain Endothelial Media  
C.3.1 Materials Required for 250 mL Media 
 Sterile filtration unit 
 233.75 mL Rat Brain Endothelial Cell Basal Media 
 15 mL Rat Brain Endothelial Growth Factor (6.0 %) 
 1.25 mL Penicillin/Streptomycin solution (P/S) (0.5 %) 
 
C.3.2 Preparation of Rat Brain Endothelial Media  
The procedure is carried out in a laminar flow hood (sterile environment). 
1. Add 100 mL Rat Brain Endothelial Cell Basal Media to the sterile filtration unit. 
2. Add Rat Brain Endothelial Growth Factor and P/S to the sterile filtration unit. 
3. Add 133.75 mL Ham’s F-12K media to the sterile filtration unit. 
4. Place the lid over the sterile filtration unit and connect it to the vacuum nozzle. 
5. Carefully turn on the vacuum and allow the liquid to pass through the filter. Make 
sure to hold the sterile filtration unit during this step so the unit does not turn 
over. Turn off the vacuum before bubbles form. 
6. Twist the top of the filtration unit off carefully. Screw the sterile cap onto the 
container of media. 
Label media as Endothelial media with the date and your initials, and store in the 
refrigerator. 
C.4 Astrocyte Media 
C.4.1 Materials Required for 250 mL Media 
 Sterile filtration unit 





 12.5 mL Fetal Bovine Serum (FBS) (5.0 %) 
 12.5 mL Horse Serum (5.0 %) 
 1.25 mL Penicillin/Streptomycin solution (P/S) (0.5 %) 
 
C.4.2 Preparation of Astrocyte Growth Media  
The procedure is carried out in a laminar flow hood (sterile environment). 
7. Add 100 mL Ham’s F-12K media to the sterile filtration unit. 
8. Add Fetal Bovine Serum, Horse Serum, and P/S to the sterile filtration unit. 
9. Add 123.75 mL Ham’s F-12K media to the sterile filtration unit. 
10. Place the lid over the sterile filtration unit and connect it to the vacuum nozzle. 
11. Carefully turn on the vacuum and allow the liquid to pass through the filter. Make 
sure to hold the sterile filtration unit during this step so the unit does not turn 
over. Turn off the vacuum before bubbles form. 
12. Twist the top of the filtration unit off carefully. Screw the sterile cap onto a 
container of media. 
13. Label media as Astrocyte media with the date and your initials, and store in the 
refrigerator. 
C.5 CRL-2303 Media 
C.5.1 Materials Required for 250 mL Media  
 Sterile filtration unit 
 221.25 mL Dulbecco’s Modified Eagle’s Medium (DMEM) 
 25 mL Fetal Bovine Serum (FBS) (10 %) 
 2.5 mL Amino acid solution (1 %) 






C.5.2 Preparation of CRL-2303 Growth Media  
The procedure is carried out in a laminar flow hood (sterile environment). 
1. Add 110.25 mL DMEM to the sterile filtration unit. 
2. Add Fetal Bovine Serum, Amino acid solution, and P/S to the sterile filtration 
unit. 
3. Add 111 mL DMEM to the sterile filtration unit. 
4. Place the lid over the sterile filtration unit and connect it to the vacuum nozzle. 
5. Carefully turn on the vacuum and allow the liquid to pass through the filter. Make 
sure to hold the sterile filtration unit during this step so the unit does not turn 
over. Turn off the vacuum before bubbles form. 
6. Twist the top of the filtration unit off carefully. Screw the sterile cap onto a 
container of media. 
7. Label media as CRL-2303 media with the date and your initials, and store in the 
refrigerator. 
C.6 Locke’s solution 
C.6.1 Materials Required for 250 mL Media 
 2250 mg of Sodium Chloride (NaCl) (154 mM) 
 104.4 mg of Potassium Chloride (KCl) (5.6 mM) 
 75.6 mg of Sodium Bicarbonate (NaHCO3) (3.6 mM) 
 84.5 mg of Calcium Chloride (CaCl2.2H2O) (2.3 mM) 





 1.25 mL of 1M stock 4-(2-hydroxyethyl)-2-piperazineethanesulfonic acid 
(HEPES) (pH 7.4) (5 mM) 
 248.75 mL of purified water 
C.6.2 Preparation of Locke’s Solution 
1. Dissolve the components in 100 mL of purified water and add them to the vacuum 
filtration unit. 
2. Add 100 mL of purified water to the vacuum filtration unit. 
3. Add water with dissolved components. 
4. Add 1.25 mL of 1 M stock HEPES. 
5. Add the remaining amount of purified water. 
6. Place cap on the unit. Carefully turn on the vacuum. 
7. Allow all the liquid to pass through the filter. Turn off the vacuum before bubbles 
form. 
8. Twist the top of the vacuum unit off carefully. Screw the sterile cap onto the 
container of the solution. 
9. Label as Locke’s solution with the date and your initials, and store in the 
refrigerator. 
Note: For preparing Locke’s solution without sodium, replace the Sodium Chloride 
with the same molarity of Choline Chloride. We don’t have any account for Sodium 
Bicarbonate. 
C.7 Fluo3/AM Loading: 
C.7.1 Materials Needed for 2ml Imaging Solution: 





2. 4µl Fluo 3/AM 3. 2ml Locke’s Solution (pre-warmed in an incubator for at least 15 
minutes)  
C.7.2 Protocol 
1. Turn off the light of the cell culture hood 
 2. Warm all components to room temperature before the experiment.  
3. Add 2ml of pre-warmed Locke’s solution to a 15 ml centrifuge tube  
4. Add 2µl pluronic acid to the tube then mix (vortex until soapsuds are observed)  
5. Add 4µl Fluo3/AM (2mg/ml in DMSO) and cap the tube.  
6. Mix the contents of the tube by gently inverting it two or three times. 
 7. Remove all media from one well then add ~500µl of loading solution to the 
emptied well. 
 8. Repeat step seven for all the wells to be imaged.  
9. Place the cell into the incubator and allow the dye to enter the cells for 45 minutes 
to an hour.  
10. Remove the loading solution and allow the cells to recover in 475µl of Locke’s 





APPENDIX D  
 
SPLITTING AND FREEZING CELLS 
D.1 Splitting Cells or Re-plating Cells  
1. Remove media from cells into a waste beaker.  
2. Wash flask once with 3 mL of 1X PBS (1 mL 10X PBS + 9 mL sterile water gives 
10 mL 1X PBS). Pipet PBS gently into a flask. Lay flask down once. Lift flask and 
remove PBS. 
3. Add 1.5 mL (for CRL-2303 and Microglia) or 3 mL (for Astrocytes) thawed 
trypsin/EDTA to flask. Cap the flask and put it in the incubator for 3 minutes (for 
CRL-2303 and Microglia) or 8 minutes (for Astrocytes). Take the flask out of the 
incubator and check under the microscope to ensure cells are detached. 
4. Add 3 mL fresh media to the flask and transfer them to a 15 ml centrifuge tube.  
5. Centrifuge cells in a tube using a counterbalance in a pre-cooled centrifuge (8°C) at 
160 r.c.f. (relative centrifugal force) for 8 minutes. 
6. After spinning, remove the supernatant liquid into the waste beaker. 
7. Suspend pellet in the desired amount of media, then vortex until cells are evenly 
distributed throughout media. 
8. Before plating, count the number of cells using a hemocytometer. 





10. Label flask with cell name, date, and passage number (passage number increases 
after splitting cells). 
D.2 Freezing Cells 
1. Remove media from cells into a waste beaker.  
2. Wash flask once with 3 mL of 1X PBS (1 mL 10X PBS + 9 mL sterile water gives 10 
mL 1X PBS). Pipet PBS gently into a flask. Lay flask down once. Lift flask and 
remove PBS. 
3. Add 1.5 mL (for CRL-2303 and Microglia) or 3 mL (for Astrocytes) thawed 
trypsin/EDTA to flask. Cap the flask and put it in the incubator for 3 minutes (for 
CRL-2303 and Microglia) or 8 minutes (for Astrocytes). Take the flask out of the 
incubator and check under the microscope to ensure cells are detached. 
4. Add 3 mL fresh media to the flask and transfer them to a 15 ml centrifuge tube.  
5. Centrifuge cells in a tube using a counterbalance in a pre-cooled centrifuge (8°C) at 
160 r.c.f. (relative centrifugal force) for 8 minutes. 
6. After spinning, remove the supernatant liquid into the waste beaker. 
7. Suspend pellet in the desired amount of media, then vortex until cells are evenly 
distributed throughout media. 
8. Add 5% DMSO dropwise to cells. Mix by inverting centrifuge tube. 
9. Transfer cell mixture to a pre-cooled cryovial.  
10.  Label cryovial with cell name, date, and passage number (passage number is the 
same as on the flask). 
11.  Put cryovials in a container and place in a -80°C freezer overnight. 





APPENDIX E  
 
THAWING AND FEEDING CELLS 
E.1 Thawing Cells  
1. Remove the vial of cells from liquid nitrogen and immediately place in a water bath 
preheated to 37°C.  
2. Thaw the vial containing cells quickly (approximately three minutes). 
3. Remove the vial, wipe the vial with Kim wipe, and isopropanol under the laminar 
flow hood. 
4. Mix cell suspension by pipetting up and down the vial. Do not vortex cells. 
5. Gently transfer the cells suspension from the vial into a flask with 5 mL pre-warmed 
cell growth media.   
6. Label flask with cell type, date, and passage number (passage number increases when 
thawing cells. 
7. Incubate the cells for 24 hr at 37°C in a 5% CO2 incubator. 
8. Do not use the cells immediately after thawing as it contains Dimethyl Sulfoxide 








E.2 Feeding Cells 
1. Remove 3 mL media from 24 cm2 flask into a waste beaker. 
2. Add 3 mL pre-warmed cell culture media to cells. 
3. Label flask with the date of feeding. 










Protocol for fixation is explained in the following steps: 
1. Remove complete media from cell culture. 
2. Wash the cells with pre-warmed Locke’s solution. 
3. Add the fixing solution (Diff Quik from Siemens) to cover the whole surface of 
the well or dish and leave it for 10 minutes. 
4. Remove the fixing solution and add Phosphate Buffer Saline (PBS) to cover the 
whole surface. 












APPENDIX G  
 
 STAINING PROTOCOLS 
G.1 DAPI Staining Protocol 
1. A 14.27 millimolar concentration of DAPI in DI water was diluted 1 to 1000 in 1x PBS.   
2. Once DAPI has been added place the dish in a 37ºC incubator for 10 minutes 
(depending on the health of the cells you may need a longer time to load to do to the 
fact that healthy cells take longer to load DAPI than damaged or dead cells). 
G.2 Diff-Quik Staining Protocol 
1. PBS was aspirated out from the fixed plate. 
2. Add 350 µl of Solution I (orange in color) from the Diff Quik staining kit to each well. 
3. Wait for 5 to 10 minutes. 
4. Take out all of Solution I from the wells and add 350 µl of Solution II (blue), from the 
staining kit to each well. 
5. Wait for 5 to 10 minutes. 
6. Take out all of Solution II from the wells. 
7. Wash 2/3 times with clean deionized water. 
8. Observe staining under the phase microscope and wash more if necessary (the staining 
is looking too dark). 





G.3 VWF Antibody (Ab) Staining 
1. Fixation of Cells:  
 Remove complete media from cell culture. 
 Wash twice the cells with pre-warmed phenol red-free RPMI solution. 
 Add 1X fixative ( ) to cover the whole surface of the well or dish and keep it for 5 
minutes. 
 Remove methanol and add 1X PBS to cover the whole surface. 
 For storage seal the plate or dish with paraffin and keep it at 2-8 ºC (in a 
refrigerator). 
2. Permeabilization of cells: Remove PBS from pre-fixed cells and 0.2 % Triton X 100 
(in 1X PBS) to cover the whole surface and keep it at room temperature for 15 minutes. 
3. Blocking: Remove Triton X 100 and add 5% Goat Serum (in 1X PBS) to cover the 
whole surface. Seal the plate or dish with paraffin and keep it at 2-8 ºC (in a refrigerator) 
for 4-5 hrs or overnight. 
4. Primary Ab: Remove goat serum and add 1° Ab (Rabbit X factor VIII in 1:500 1X 
PBS) to cover the whole surface. Seal the plate or dish with paraffin and keep it at 2-8 
ºC (in a refrigerator) for 24 hrs or overnight. 
5. Washing: Remove 1° Ab and wash twice with 1X PBS. 
6. Secondary Ab: Add 2° Ab (1:500 Goat Anti- Rabbit Ig Ab in 2% Goat Serum which is 
in 1X PBS) to cover the whole surface. Seal the plate or dish with paraffin and cover 
with aluminum foil and keep it at room temperature for 45-60 minutes. 
7. Washing: Remove 2° Ab and wash twice with 0.2 % Triton X 100 (in 1X PBS). Lastly, 





8. Fluorescence Microscopy: Observe staining using a fluorescent microscope. 
9. Storage: Seal the plate or dish with paraffin and cover with aluminum foil and keep it 
at 2-8 ºC (in a refrigerator) for storage for weeks. 
G.4 GFAP Antibody (Ab) Staining 
1. Fixation of Cells:  
 Remove complete media from cell culture. 
 Wash twice the cells with pre-warmed Locke’s solution. 
 Add ice-cold methanol to cover the whole surface of the well or dish and keep it 
for 5 minutes. 
 Remove methanol and add 1X PBS to cover the whole surface. 
 For storage seal the plate or dish with paraffin and keep it at 2-8 ºC (in a 
refrigerator). 
2. Permeabilization of cells: Remove PBS from pre-fixed cells and 0.2 % Triton X 100 
(in 1X PBS) to cover the whole surface and keep it at room temperature for 15 minutes. 
3. Blocking: Remove Triton X 100 and add 2% Goat Serum (in 1X PBS) to cover the 
whole surface. Seal the plate or dish with paraffin and keep it at 2-8 ºC (in a refrigerator) 
for 4-5 hrs or overnight. 
4. Primary Ab: Remove goat serum and add 1° Ab (Anti-GFAP produced in rabbit in 
1:500 1X PBS) to cover the whole surface. Seal the plate or dish with paraffin and keep 
it at 2-8 ºC (in a refrigerator) for 24 hrs or overnight. 





6. Secondary Ab: Add 2° Ab (1:500 Goat Anti- Rabbit Ig Ab in 2% Goat Serum which is 
in 1X PBS) to cover the whole surface. Seal the plate or dish with paraffin and cover 
with aluminum foil and keep it at room temperature for 45-60 minutes. 
7. Washing: Remove 2° Ab and wash twice with 0.2 % Triton X 100 (in 1X PBS). Lastly, 
add 1X PBS to cover the whole surface. 
8. Fluorescence Microscopy: Observe staining using a fluorescent microscope. 
9. Storage: Seal the plate or dish with paraffin and cover with aluminum foil and keep it 














APPENDIX H  
 
MTT ASSAY PROTOCOL 
 
400 µL of MTT solution is added into each well of a 24 well plate. Considering this, 9.6 
mL of MTT would be needed to treat an entire plate. Usually, 11 mL of solution is 
prepared to have a buffer volume. 
Procedure for a 24 well plate: 
1. Weigh 13.75 mg of MTT powder and add it to 11 mL of prewarmed DMEM 
without phenol red (or sterile Locke’s solution). 
2. Media is aspirated from the wells carefully. Do not wash. 
3. Add 400 uL of MTT solution carefully to each well from the side. 
4. Place the 24 well plates in the incubator for 60 minutes to allow the cells to react 
with the MTT solution. 
5. The viable cells react, and purple crystals are formed in the wells. 
6. After incubation, aspirate the MTT solution carefully without lifting the crystals 
and add 300 µL of 91% isopropanol to each well. 
7. Allow the crystals to be dissolved into the isopropanol, gently shake the well 
plate. Don’t delay after adding the isopropanol as it will evaporate. 
8. Transfer 300 µL of isopropanol with dissolved crystals into 96 well plates. 





APPENDIX I  
 
NO ASSAY PROTOCOL 
 
I.1  Materials Required 
Griess Reagent: 
i) N-(1-naphthyl)ethylenediamine (Component A), , 25 mL of a 
0.1% (1 mg/mL) solution, sealed under argon 
ii) Sulfanilic acid (Component B), 25 mL of a 1% (10 mg/mL) 
solution in 5% phosphoric acid 
iii) Nitrite standard solution (Component C), 1.0 mL of 1.0 mM 
sodium nitrite in deionized water 
I.2  Protocol 
1. Mix the following in a 1.5 or 2mL Eppendorf tube for preparing a solution of 1 
mL for each sample. 
i) 866.5 µL of non-sterile water 
ii) 100 µL of media from the cells 
ii) 33.5 µL of Griess Reagent (A and B in equal volume)  
2. Prepare a photometric reference sample by using the Nitrite standard solution 
(Component C) of Griess Reagent (as shown in step 1, replacing the media (ii) 
with different concentrations of Component C). 





4.  Incubate the mixture for 30 minutes in dark at room temperature. 
5. Measure the absorbance of the nitrite-containing sample at 548 nm relative to the 
reference sample. 
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